Last updated

Cloth embroidered by a schizophrenia sufferer.jpg
Cloth embroidered by a person diagnosed with schizophrenia
Specialty Psychiatry [1]
Symptoms Hallucinations, delusions, confused thinking and behavior, flat or inappropriate affect [2] [3]
Complications harm to self or other, social isolation, cognitive issues, heart disease, lifestyle diseases, [4] obesity and type 2 diabetes arising from antipsychotic medication [5] [6]
Usual onsetAges 16 to 30 [3]
DurationChronic [3]
CausesEnvironmental and genetic factors [7]
Risk factors Family history, cannabis use in adolescence, consumption of hallucinogens or amphetamines, [8] problems during pregnancy, childhood adversity, birth in late winter or early spring, older father, being born or raised in a city [7] [9]
Diagnostic method Based on observed behavior, reported experiences, and reports of others familiar with the person [10]
Differential diagnosis Substance use disorder, Huntington's disease, mood disorders (bipolar disorder, major depressive disorder), autism, [11] borderline personality disorder, [12] schizophreniform disorder, schizotypal personality disorder, schizoid personality disorder, antisocial personality disorder, psychotic depression, anxiety, disruptive mood dysregulation disorder, sleep paralysis
ManagementCounseling, life skills training [2] [7]
Medication Antipsychotics [7]
Prognosis 20–28 years shorter life expectancy [13] [14]
Frequency~0.32% (1 in 300) of the global population is affected. [15]
Deaths~17,000 (2015) [16]

Schizophrenia is a mental disorder [17] characterized by reoccurring episodes of psychosis that are correlated with a general misperception of reality. [7] Other common signs include hallucinations (typically hearing voices), delusions (i.e., paranoia), disorganized thinking and behavior, [10] social withdrawal, and flat or inappropriate affect. [7] Symptoms develop gradually and typically begin during young adulthood and are never resolved. [3] [10] There is no objective diagnostic test; diagnosis is based on observed behavior, a psychiatric history that includes the person's reported experiences, and reports of others familiar with the person. [10] For a diagnosis of schizophrenia, the described symptoms need to have been present for at least six months (according to the DSM-5) or one month (according to the ICD-11). [10] [18] Many people with schizophrenia have other mental disorders, especially substance use disorders, depressive disorders, anxiety disorders, and obsessive–compulsive disorder. [10]


About 0.3% to 0.7% of people are diagnosed with schizophrenia during their lifetime. [19] In 2017, there were an estimated 1.1 million new cases and in 2022 a total of 24 million cases globally. [2] [20] Males are more often affected and on average have an earlier onset than females. [2] The causes of schizophrenia may include genetic and environmental factors. [7] Genetic factors include a variety of common and rare genetic variants. [21] Possible environmental factors include being raised in a city, childhood adversity, cannabis use during adolescence, infections, the age of a person's mother or father, and poor nutrition during pregnancy. [7] [22]

About half of those diagnosed with schizophrenia will have a significant improvement over the long term with no further relapses, and a small proportion of these will recover completely. [10] [23] The other half will have a lifelong impairment. [24] In severe cases, people may be admitted to hospitals. [23] Social problems such as long-term unemployment, poverty, homelessness, exploitation and victimization are commonly correlated with schizophrenia. [25] [26] Compared to the general population, people with schizophrenia have a higher suicide rate (about 5% overall) and more physical health problems, [27] [28] leading to an average decrease in life expectancy by 20 [13] to 28 years. [14] In 2015, an estimated 17,000 deaths were linked to schizophrenia. [16]

The mainstay of treatment is antipsychotic medication, including olanzapine and risperidone, along with counseling, job training and social rehabilitation. [7] Up to a third of people do not respond to initial antipsychotics, in which case clozapine gained approval by the US Food and Drug Administration for treatment-resistant cases. [29] In a network comparative meta-analysis of 15 antipsychotic drugs, clozapine was significantly more effective than all other drugs, although clozapine's heavily multimodal action may cause more significant side effects. [30] In situations where doctors judge that there is a risk of harm to self or others, they may impose short involuntary hospitalization. [31] Long-term hospitalization is used on a small number of people with severe schizophrenia. [32] In some countries where supportive services are limited or unavailable, long-term hospital stays are more common. [33]

Signs and symptoms

My Eyes at the Moment of the Apparitions by German artist August Natterer, who had schizophrenia August Natterer Meine Augen zur Zeit der Erscheinungen.jpg
My Eyes at the Moment of the Apparitions by German artist August Natterer, who had schizophrenia

Schizophrenia is a mental disorder characterized by significant alterations in perception, thoughts, mood, and behavior. [34] Symptoms are described in terms of positive, negative and cognitive symptoms. [3] [35] The positive symptoms of schizophrenia are the same for any psychosis and are sometimes referred to as psychotic symptoms. These may be present in any of the different psychoses and are often transient, making early diagnosis of schizophrenia problematic. Psychosis noted for the first time in a person who is later diagnosed with schizophrenia is referred to as a first-episode psychosis (FEP). [36] [37]

Positive symptoms

Positive symptoms are those symptoms that are not normally experienced, but are present in people during a psychotic episode in schizophrenia, including delusions, hallucinations, and disorganized thoughts, speech and behavior or inappropriate affect, typically regarded as manifestations of psychosis. [36] Hallucinations occur at some point in the lifetimes of 80% of those with schizophrenia [38] and most commonly involve the sense of hearing (most often hearing voices), but can sometimes involve any of the other senses of taste, sight, smell and touch. [39] The frequency of hallucinations involving multiple senses is double the rate of those involving only one sense. [38] They are also typically related to the content of the delusional theme. [40] Delusions are bizarre or persecutory in nature. Distortions of self-experience such as feeling that others can hear one's thoughts or that thoughts are being inserted into one's mind, sometimes termed passivity phenomena, are also common. [41] [3] Positive symptoms generally respond well to medication [7] and become reduced over the course of the illness, perhaps linked to the age-related decline in dopamine activity. [10]

Negative symptoms

Negative symptoms are deficits of normal emotional responses, or of other thought processes. The five recognized domains of negative symptoms are: blunted affect – showing flat expressions (monotone) or little emotion; alogia – a poverty of speech; anhedonia – an inability to feel pleasure; asociality – the lack of desire to form relationships, and avolition – a lack of motivation and apathy. [42] [43] Avolition and anhedonia are seen as motivational deficits resulting from impaired reward processing. [44] [45] Reward is the main driver of motivation and this is mostly mediated by dopamine. [45] It has been suggested that negative symptoms are multidimensional and they have been categorised into two subdomains of apathy or lack of motivation, and diminished expression. [42] [46] Apathy includes avolition, anhedonia, and social withdrawal; diminished expression includes blunt affect and alogia. [47] Sometimes diminished expression is treated as both verbal and non-verbal. [48]

Apathy accounts for around 50 percent of the most often found negative symptoms and affects functional outcome and subsequent quality of life. Apathy is related to disrupted cognitive processing affecting memory and planning including goal-directed behaviour. [49] The two subdomains have suggested a need for separate treatment approaches. [50] A lack of distress is another noted negative symptom. [51] A distinction is often made between those negative symptoms that are inherent to schizophrenia, termed primary; and those that result from positive symptoms, from the side effects of antipsychotics, substance use disorder, and social deprivation – termed secondary negative symptoms. [52] Negative symptoms are less responsive to medication and the most difficult to treat. [50] However, if properly assessed, secondary negative symptoms are amenable to treatment. [46]

Scales for specifically assessing the presence of negative symptoms, and for measuring their severity, and their changes have been introduced since the earlier scales such as the PANNS that deals with all types of symptoms. [50] These scales are the Clinical Assessment Interview for Negative Symptoms (CAINS), and the Brief Negative Symptom Scale (BNSS) also known as second-generation scales. [50] [51] [53] In 2020, ten years after its introduction, a cross-cultural study of the use of BNSS found valid and reliable psychometric evidence for its five-domain structure cross-culturally. The BNSS can assess both the presence and severity of negative symptoms of the five recognized domains and an additional item of reduced normal distress. It has been used to measure changes in negative symptoms in trials of psychosocial and pharmacological interventions. [51]

Cognitive symptoms

Map of deficits in neural tissue throughout the human brain in a patient with schizophrenia. The most deficient areas are magenta, while the least deficient areas are blue. SchizophreniaBrain.jpg
Map of deficits in neural tissue throughout the human brain in a patient with schizophrenia. The most deficient areas are magenta, while the least deficient areas are blue.

An estimated 70% of those with schizophrenia have cognitive deficits, and these are most pronounced in early-onset and late-onset illness. [54] [55] These are often evident long before the onset of illness in the prodromal stage, and may be present in childhood or early adolescence. [56] [57] They are a core feature but not considered to be core symptoms, as are positive and negative symptoms. [58] [59] However, their presence and degree of dysfunction is taken as a better indicator of functionality than the presentation of core symptoms. [56] Cognitive deficits become worse at first episode psychosis but then return to baseline, and remain fairly stable over the course of the illness. [60] [61]

The deficits in cognition are seen to drive the negative psychosocial outcome in schizophrenia, and are claimed[ who? ] to equate to a possible reduction in IQ from the norm of 100 to 70–85. [62] [63] Cognitive deficits may be of neurocognition (nonsocial) or of social cognition. [54] Neurocognition is the ability to receive and remember information, and includes verbal fluency, memory, reasoning, problem solving, speed of processing, and auditory and visual perception. [61] Verbal memory and attention are seen to be the most affected. [63] [64] Verbal memory impairment is associated with a decreased level of semantic processing (relating meaning to words). [65] Another memory impairment is that of episodic memory. [66] An impairment in visual perception that is consistently found in schizophrenia is that of visual backward masking. [61] Visual processing impairments include an inability to perceive complex visual illusions. [67] Social cognition is concerned with the mental operations needed to interpret, and understand the self and others in the social world. [61] [54] This is also an associated impairment, and facial emotion perception is often found to be difficult. [68] [69] Facial perception is critical for ordinary social interaction. [70] Cognitive impairments do not usually respond to antipsychotics, and there are a number of interventions that are used to try to improve them; cognitive remediation therapy is of particular help. [59]

Neurological soft signs of clumsiness and loss of fine motor movement are often found in schizophrenia, which may resolve with effective treatment of FEP. [18] [71]


Onset typically occurs between the late teens and early 30s, with the peak incidence occurring in males in the early to mid-twenties, and in females in the late twenties. [3] [10] [18] Onset before the age of 17 is known as early-onset, [72] and before the age of 13, as can sometimes occur, is known as childhood schizophrenia or very early-onset. [10] [73] Onset can occur between the ages of 40 and 60, known as late-onset schizophrenia. [54] Onset over the age of 60, which may be difficult to differentiate as schizophrenia, is known as very-late-onset schizophrenia-like psychosis. [54] Late onset has shown that a higher rate of females are affected; they have less severe symptoms and need lower doses of antipsychotics. [54] The tendency for earlier onset in males is later seen to be balanced by a post-menopausal increase in the development in females. Estrogen produced pre-menopause has a dampening effect on dopamine receptors but its protection can be overridden by a genetic overload. [74] There has been a dramatic increase in the numbers of older adults with schizophrenia. [75]

Onset may happen suddenly or may occur after the slow and gradual development of a number of signs and symptoms, a period known as the prodromal stage. [10] Up to 75% of those with schizophrenia go through a prodromal stage. [76] The negative and cognitive symptoms in the prodrome stage can precede FEP (first episode psychosis) by many months and up to five years. [60] [77] The period from FEP and treatment is known as the duration of untreated psychosis (DUP) which is seen to be a factor in functional outcome. The prodromal stage is the high-risk stage for the development of psychosis. [61] Since the progression to first episode psychosis is not inevitable, an alternative term is often preferred of at risk mental state. [61] Cognitive dysfunction at an early age impacts a young person's usual cognitive development. [78] Recognition and early intervention at the prodromal stage would minimize the associated disruption to educational and social development and has been the focus of many studies. [60] [77]

Risk factors

Schizophrenia is described as a neurodevelopmental disorder with no precise boundary, or single cause, and is thought to develop from gene–environment interactions with involved vulnerability factors. [7] [79] [80] The interactions of these risk factors are complex, as numerous and diverse insults from conception to adulthood can be involved. [80] A genetic predisposition on its own, without interacting environmental factors, will not give rise to the development of schizophrenia. [80] [81] The genetic component means that prenatal brain development is disturbed, and environmental influence affects the postnatal development of the brain. [82] Evidence suggests that genetically susceptible children are more likely to be vulnerable to the effects of environmental risk factors. [82]


Estimates of the heritability of schizophrenia are between 70% and 80%, which implies that 70% to 80% of the individual differences in risk of schizophrenia are associated with genetics. [21] [83] These estimates vary because of the difficulty in separating genetic and environmental influences, and their accuracy has been queried. [84] [85] The greatest risk factor for developing schizophrenia is having a first-degree relative with the disease (risk is 6.5%); more than 40% of identical twins of those with schizophrenia are also affected. [86] If one parent is affected the risk is about 13% and if both are affected the risk is nearly 50%. [83] However, the DSM-5 indicates that most people with schizophrenia have no family history of psychosis. [10] Results of candidate gene studies of schizophrenia have generally failed to find consistent associations, [87] and the genetic loci identified by genome-wide association studies explain only a small fraction of the variation in the disease. [88]

Many genes are known to be involved in schizophrenia, each with small effects and unknown transmission and expression. [21] [89] [90] The summation of these effect sizes into a polygenic risk score can explain at least 7% of the variability in liability for schizophrenia. [91] Around 5% of cases of schizophrenia are understood to be at least partially attributable to rare copy number variations (CNVs); these structural variations are associated with known genomic disorders involving deletions at 22q11.2 (DiGeorge syndrome) and 17q12 (17q12 microdeletion syndrome), duplications at 16p11.2 (most frequently found) and deletions at 15q11.2 (Burnside–Butler syndrome). [92] Some of these CNVs increase the risk of developing schizophrenia by as much as 20-fold, and are frequently comorbid with autism and intellectual disabilities. [92]

The genes CRHR1 and CRHBP are associated with the severity of suicidal behavior. These genes code for stress response proteins needed in the control of the HPA axis, and their interaction can affect this axis. Response to stress can cause lasting changes in the function of the HPA axis possibly disrupting the negative feedback mechanism, homeostasis, and the regulation of emotion leading to altered behaviors. [81]

The question of how schizophrenia could be primarily genetically influenced, given that people with schizophrenia have lower fertility rates, is a paradox. It is expected that genetic variants that increase the risk of schizophrenia would be selected against, due to their negative effects on reproductive fitness. A number of potential explanations have been proposed, including that alleles associated with schizophrenia risk confers a fitness advantage in unaffected individuals. [93] [94] While some evidence has not supported this idea, [85] others propose that a large number of alleles each contributing a small amount can persist. [95]

A meta-analysis found that oxidative DNA damage was significantly increased in schizophrenia. [96]


Environmental factors, each associated with a slight risk of developing schizophrenia in later life include oxygen deprivation, infection, prenatal maternal stress, and malnutrition in the mother during prenatal development. [97] A risk is associated with maternal obesity, in increasing oxidative stress, and dysregulating the dopamine and serotonin pathways. [98] Both maternal stress and infection have been demonstrated to alter fetal neurodevelopment through an increase of pro-inflammatory cytokines. [99] There is a slighter risk associated with being born in the winter or spring possibly due to vitamin D deficiency [100] or a prenatal viral infection. [86] Other infections during pregnancy or around the time of birth that have been linked to an increased risk include infections by Toxoplasma gondii and Chlamydia . [101] The increased risk is about five to eight percent. [102] Viral infections of the brain during childhood are also linked to a risk of schizophrenia during adulthood. [103] Cat exposure may also serve as a risk factor. [104]

Adverse childhood experiences (ACEs), severe forms of which are classed as childhood trauma, range from being bullied or abused, to the death of a parent. [105] Many adverse childhood experiences can cause toxic stress and increase the risk of psychosis. [105] [106] [107] Chronic trauma, including ACEs, can promote lasting inflammatory dysregulation throughout the nervous system. [108] It is suggested that early stress may contribute to the development of schizophrenia through these alterations in the immune system. [108] Schizophrenia was the last diagnosis to benefit from the link made between ACEs and adult mental health outcomes. [109]

Living in an urban environment during childhood or as an adult has consistently been found to increase the risk of schizophrenia by a factor of two, [27] [110] even after taking into account drug use, ethnic group, and size of social group. [111] A possible link between the urban environment and pollution has been suggested to be the cause of the elevated risk of schizophrenia. [112] Other risk factors include social isolation, immigration related to social adversity and racial discrimination, family dysfunction, unemployment, and poor housing conditions. [86] [113] Having a father older than 40 years, or parents younger than 20 years are also associated with schizophrenia. [7] [114]

Substance use

About half of those with schizophrenia use recreational drugs including alcohol, tobacco, and cannabis excessively. [115] [116] Use of stimulants such as amphetamine and cocaine can lead to a temporary stimulant psychosis, which presents very similarly to schizophrenia. Rarely, alcohol use can also result in a similar alcohol-related psychosis. [86] [117] Drugs may also be used as coping mechanisms by people who have schizophrenia, to deal with depression, anxiety, boredom, and loneliness. [115] [118] The use of cannabis and tobacco are not associated with the development of cognitive deficits, and sometimes a reverse relationship is found where their use improves these symptoms. [59] However, substance use disorders are associated with an increased risk of suicide, and a poor response to treatment. [119] [120]

Cannabis use may be a contributory factor in the development of schizophrenia, potentially increasing the risk of the disease in those who are already at risk. [121] [122] [123] The increased risk may require the presence of certain genes within an individual. [22] Its use is associated with doubling the rate. [124]


The causes of schizophrenia are unknown, and a number of models have been put forward to explain the link between altered brain function and schizophrenia. [27] The prevailing model of schizophrenia is that of a neurodevelopmental disorder, and the underlying changes that occur before symptoms become evident are seen as arising from the interaction between genes and the environment. [125] Extensive studies support this model. [76] Maternal infections, malnutrition and complications during pregnancy and childbirth are known risk factors for the development of schizophrenia, which usually emerges between the ages of 18 and 25, a period that overlaps with certain stages of neurodevelopment. [126] Gene-environment interactions lead to deficits in the neural circuitry that affect sensory and cognitive functions. [76]

The common dopamine and glutamate models proposed are not mutually exclusive; each is seen to have a role in the neurobiology of schizophrenia. [127] The most common model put forward was the dopamine hypothesis of schizophrenia, which attributes psychosis to the mind's faulty interpretation of the misfiring of dopaminergic neurons. [128] This has been directly related to the symptoms of delusions and hallucinations. [129] [130] [131] Abnormal dopamine signaling has been implicated in schizophrenia based on the usefulness of medications that affect the dopamine receptor and the observation that dopamine levels are increased during acute psychosis. [132] [133] A decrease in D1 receptors in the dorsolateral prefrontal cortex may also be responsible for deficits in working memory. [134] [135]

The glutamate hypothesis of schizophrenia links alterations between glutamatergic neurotransmission and the neural oscillations that affect connections between the thalamus and the cortex. [136] Studies have shown that a reduced expression of a glutamate receptorNMDA receptor, and glutamate blocking drugs such as phencyclidine and ketamine can mimic the symptoms and cognitive problems associated with schizophrenia. [136] [137] [138] Post-mortem studies consistently find that a subset of these neurons fail to express GAD67 (GAD1), [139] in addition to abnormalities in brain morphometry. The subsets of interneurons that are abnormal in schizophrenia are responsible for the synchronizing of neural ensembles needed during working memory tasks. These give the neural oscillations produced as gamma waves that have a frequency of between 30 and 80 hertz. Both working memory tasks and gamma waves are impaired in schizophrenia, which may reflect abnormal interneuron functionality. [139] [140] [141] [142] An important process that may be disrupted in neurodevelopment is astrogenesis – the formation of astrocytes. Astrocytes are crucial in contributing to the formation and maintenance of neural circuits and it is believed that disruption in this role can result in a number of neurodevelopmental disorders including schizophrenia. [143] Evidence suggests that reduced numbers of astrocytes in deeper cortical layers are assocociated with a diminished expression of EAAT2, a glutamate transporter in astrocytes; supporting the glutamate hypothesis. [143]

Deficits in executive functions, such as planning, inhibition, and working memory, are pervasive in schizophrenia. Although these functions are separable, their dysfunction in schizophrenia may reflect an underlying deficit in the ability to represent goal related information in working memory, and to use this to direct cognition and behavior. [144] [145] These impairments have been linked to a number of neuroimaging and neuropathological abnormalities. For example, functional neuroimaging studies report evidence of reduced neural processing efficiency, whereby the dorsolateral prefrontal cortex is activated to a greater degree to achieve a certain level of performance relative to controls on working memory tasks. These abnormalities may be linked to the consistent post-mortem finding of reduced neuropil, evidenced by increased pyramidal cell density and reduced dendritic spine density. These cellular and functional abnormalities may also be reflected in structural neuroimaging studies that find reduced grey matter volume in association with deficits in working memory tasks. [146]

Positive symptoms have been linked to cortical thinning in the superior temporal gyrus. [147] The severity of negative symptoms has been linked to reduced thickness in the left medial orbitofrontal cortex. [148] Anhedonia, traditionally defined as a reduced capacity to experience pleasure, is frequently reported in schizophrenia. However, a large body of evidence suggests that hedonic responses are intact in schizophrenia, [149] and that what is reported to be anhedonia is a reflection of dysfunction in other processes related to reward. [150] Overall, a failure of reward prediction is thought to lead to impairment in the generation of cognition and behavior required to obtain rewards, despite normal hedonic responses. [151]

Another theory links abnormal brain lateralization to the development of being left-handed which is significantly more common in those with schizophrenia. [152] This abnormal development of hemispheric asymmetry is noted in schizophrenia. [153] Studies have concluded that the link is a true and verifiable effect that may reflect a genetic link between lateralization and schizophrenia. [152] [154]

Bayesian models of brain functioning have been used to link abnormalities in cellular functioning to symptoms. [155] [156] Both hallucinations and delusions have been suggested to reflect improper encoding of prior expectations, thereby causing expectation to excessively influence sensory perception and the formation of beliefs. In approved models of circuits that mediate predictive coding, reduced NMDA receptor activation, could in theory result in the positive symptoms of delusions and hallucinations. [157] [158] [159]



Schizophrenia is diagnosed based on criteria in either the Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association or the International Statistical Classification of Diseases and Related Health Problems (ICD) published by the World Health Organization (WHO). These criteria use the self-reported experiences of the person and reported abnormalities in behavior, followed by a psychiatric assessment. The mental status examination is an important part of the assessment. [160] An established tool for assessing the severity of positive and negative symptoms is the Positive and Negative Syndrome Scale (PANSS). [161] This has been seen to have shortcomings relating to negative symptoms, and other scales – the Clinical Assessment Interview for Negative Symptoms (CAINS), and the Brief Negative Symptoms Scale (BNSS) have been introduced. [50] The DSM-5, published in 2013, gives a Scale to Assess the Severity of Symptom Dimensions outlining eight dimensions of symptoms. [58]

DSM-5 states that to be diagnosed with schizophrenia, two diagnostic criteria have to be met over the period of one month, with a significant impact on social or occupational functioning for at least six months. One of the symptoms needs to be either delusions, hallucinations, or disorganized speech. A second symptom could be one of the negative symptoms, or severely disorganized or catatonic behaviour. [10] A different diagnosis of schizophreniform disorder can be made before the six months needed for the diagnosis of schizophrenia. [10]

In Australia, the guideline for diagnosis is for six months or more with symptoms severe enough to affect ordinary functioning. [162] In the UK diagnosis is based on having the symptoms for most of the time for one month, with symptoms that significantly affect the ability to work, study, or carry on ordinary daily living, and with other similar conditions ruled out. [163]

The ICD criteria are typically used in European countries; the DSM criteria are used predominantly in the United States and Canada, and are prevailing in research studies. In practice, agreement between the two systems is high. [164] The current proposal for the ICD-11 criteria for schizophrenia recommends adding self-disorder as a symptom. [41]

A major unresolved difference between the two diagnostic systems is that of the requirement in DSM of an impaired functional outcome. WHO for ICD argues that not all people with schizophrenia have functional deficits and so these are not specific for the diagnosis. [58]


Euler diagram showing overlapping clinical phenotypes in genes associated with monogenic forms of autism spectrum disorder (ASD), dystonia, epilepsy and schizophrenia:
.mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{}
Genes associated with epilepsy
Genes associated with schizophrenia
Genes associated with autism spectrum disorder
Genes associated with dystonia Overlapping clinical phenotypes in genes associated with monogenic forms of autism spectrum disorder (ASD), dystonia, epilepsy and schizophrenia.svg
Euler diagram showing overlapping clinical phenotypes in genes associated with monogenic forms of autism spectrum disorder (ASD), dystonia, epilepsy and schizophrenia:
  Genes associated with epilepsy
  Genes associated with schizophrenia
  Genes associated with autism spectrum disorder
  Genes associated with dystonia

Many people with schizophrenia may have one or more other mental disorders, such as anxiety disorders, obsessive–compulsive disorder, or substance use disorder. These are separate disorders that require treatment. [10] When comorbid with schizophrenia, substance use disorder and antisocial personality disorder both increase the risk for violence. [165] Comorbid substance use disorder also increases the risk of suicide. [119]

Sleep disorders often co-occur with schizophrenia, and may be an early sign of relapse. [166] Sleep disorders are linked with positive symptoms such as disorganized thinking and can adversely affect cortical plasticity and cognition. [166] The consolidation of memories is disrupted in sleep disorders. [167] They are associated with severity of illness, a poor prognosis, and poor quality of life. [168] [169] Sleep onset and maintenance insomnia is a common symptom, regardless of whether treatment has been received or not. [168] Genetic variations have been found associated with these conditions involving the circadian rhythm, dopamine and histamine metabolism, and signal transduction. [170]

Schizophrenia is also associated with a number of somatic comorbidities including diabetes mellitus type 2, autoimmune diseases, and cardiovascular diseases. The association of these with schizophrenia may be partially due to medications (e.g. dyslipidemia from antipsychotics), environmental factors (e.g. complications from an increased rate of cigarette smoking), or associated with the disorder itself (e.g. diabetes mellitus type 2 and some cardiovascular diseases are thought to be genetically linked). These somatic comorbidities contribute to reduced life expectancy among persons with the disorder. [171]

Differential diagnosis

To make a diagnosis of schizophrenia other possible causes of psychosis need to be excluded. [172] :858 Psychotic symptoms lasting less than a month may be diagnosed as brief psychotic disorder, or as schizophreniform disorder. Psychosis is noted in Other specified schizophrenia spectrum and other psychotic disorders as a DSM-5 category. Schizoaffective disorder is diagnosed if symptoms of mood disorder are substantially present alongside psychotic symptoms. Psychosis that results from a general medical condition or substance is termed secondary psychosis. [10]

Psychotic symptoms may be present in several other conditions, including bipolar disorder, [11] borderline personality disorder, [12] substance intoxication, substance-induced psychosis, and a number of drug withdrawal syndromes. Non-bizarre delusions are also present in delusional disorder, and social withdrawal in social anxiety disorder, avoidant personality disorder and schizotypal personality disorder. Schizotypal personality disorder has symptoms that are similar but less severe than those of schizophrenia. [10] Schizophrenia occurs along with obsessive–compulsive disorder (OCD) considerably more often than could be explained by chance, although it can be difficult to distinguish obsessions that occur in OCD from the delusions of schizophrenia. [173] There can be considerable overlap with the symptoms of post-traumatic stress disorder. [174]

A more general medical and neurological examination may be needed to rule out medical illnesses which may rarely produce psychotic schizophrenia-like symptoms, such as metabolic disturbance, systemic infection, syphilis, HIV-associated neurocognitive disorder, epilepsy, limbic encephalitis, and brain lesions. Stroke, multiple sclerosis, hyperthyroidism, hypothyroidism, and dementias such as Alzheimer's disease, Huntington's disease, frontotemporal dementia, and the Lewy body dementias may also be associated with schizophrenia-like psychotic symptoms. [175] It may be necessary to rule out a delirium, which can be distinguished by visual hallucinations, acute onset and fluctuating level of consciousness, and indicates an underlying medical illness. Investigations are not generally repeated for relapse unless there is a specific medical indication or possible adverse effects from antipsychotic medication. [176] In children hallucinations must be separated from typical childhood fantasies. [10] It is difficult to distinguish childhood schizophrenia from autism. [73]


Prevention of schizophrenia is difficult as there are no reliable markers for the later development of the disorder. [177]

Early intervention programs diagnose and treat patients in the prodromal phase of the illness. There is some evidence that these programs reduce symptoms. Patients tend to prefer early treatment programs to ordinary treatment and are less likely to disengage from them. As of 2020, it is unclear whether the benefits of early treatment persist once the treatment is terminated. [178]

Cognitive behavioral therapy may reduce the risk of psychosis in those at high risk after a year [179] and is recommended in this group, by the National Institute for Health and Care Excellence (NICE). [34] Another preventive measure is to avoid drugs that have been associated with development of the disorder, including cannabis, cocaine, and amphetamines. [86]

Antipsychotics are prescribed following a first-episode psychosis, and following remission, a preventive maintenance use is continued to avoid relapse. However, it is recognized that some people do recover following a single episode and that long-term use of antipsychotics will not be needed but there is no way of identifying this group. [180]


The primary treatment of schizophrenia is the use of antipsychotic medications, often in combination with psychosocial interventions and social supports. [27] [181] Community support services including drop-in centers, visits by members of a community mental health team, supported employment, [182] and support groups are common. The time between the onset of psychotic symptoms to being given treatment – the duration of untreated psychosis (DUP) – is associated with a poorer outcome in both the short term and the long term. [183]

Voluntary or involuntary admission to hospital may be imposed by doctors and courts who deem a person to be having a severe episode. In the UK, large mental hospitals termed asylums began to be closed down in the 1950s with the advent of antipsychotics, and with an awareness of the negative impact of long-term hospital stays on recovery. [25] This process was known as deinstitutionalization, and community and supportive services were developed to support this change. Many other countries followed suit with the US starting in the 60s. [184] There still remain a smaller group of people who do not improve enough to be discharged. [25] [32] In some countries that lack the necessary supportive and social services, long-term hospital stays are more usual. [33]


Risperidone (trade name Risperdal) is a common atypical antipsychotic medication. Risperdal tablets.jpg
Risperidone (trade name Risperdal) is a common atypical antipsychotic medication.

The first-line treatment for schizophrenia is an antipsychotic. The first-generation antipsychotics, now called typical antipsychotics like Flupentixol, are dopamine antagonists that block D2 receptors, and affect the neurotransmission of dopamine. Those brought out later, the second-generation antipsychotics known as atypical antipsychotics, including olanzapine and risperidone, can also have an effect on another neurotransmitter, serotonin. Antipsychotics can reduce the symptoms of anxiety within hours of their use but for other symptoms they may take several days or weeks to reach their full effect. [36] [185] They have little effect on negative and cognitive symptoms, which may be helped by additional psychotherapies and medications. [186] There is no single antipsychotic suitable for first-line treatment for everyone, as responses and tolerances vary between people. [187] Stopping medication may be considered after a single psychotic episode where there has been a full recovery with no symptoms for twelve months. Repeated relapses worsen the long-term outlook and the risk of relapse following a second episode is high, and long-term treatment is usually recommended. [188] [189]

About half of those with schizophrenia will respond favourably to antipsychotics, and have a good return of functioning. [190] However, positive symptoms persist in up to a third of people. Following two trials of different antipsychotics over six weeks, that also prove ineffective, they will be classed as having treatment resistant schizophrenia (TRS), and clozapine will be offered. [191] [29] Clozapine is of benefit to around half of this group although it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people. [27] [86] [192]

About 30 to 50 percent of people with schizophrenia do not accept that they have an illness or comply with their recommended treatment. [193] For those who are unwilling or unable to take medication regularly, long-acting injections of antipsychotics may be used, [194] which reduce the risk of relapse to a greater degree than oral medications. [195] When used in combination with psychosocial interventions, they may improve long-term adherence to treatment. [196]

Adverse effects

Extrapyramidal symptoms, including akathisia, are associated with all commercially available antipsychotic to varying degrees. [197] :566 There is little evidence that second generation antipsychotics have reduced levels of extrapyramidical symptoms compared to typical antipsychotics. [197] :566 Tardive dyskinesia can occur due to long-term use of antipsychotics, developing after months or years of use. [198] The antipsychotic clozapine is also associated with thromboembolism (including pulmonary embolism), myocarditis, and cardiomyopathy.

Psychosocial interventions

A number of psychosocial interventions that include several types of psychotherapy may be useful in the treatment of schizophrenia such as: family therapy, [199] group therapy, cognitive remediation therapy (CRT), [200] cognitive behavioral therapy (CBT), and metacognitive training. [201] [202] Skills training, help with substance use, and weight management – often needed as a side effect of an antipsychotic – are also offered. [203] In the US, interventions for first episode psychosis have been brought together in an overall approach known as coordinated speciality care (CSC) and also includes support for education. [36] In the UK care across all phases is a similar approach that covers many of the treatment guidelines recommended. [34] The aim is to reduce the number of relapses and stays in the hospital. [199]

Other support services for education, employment, and housing are usually offered. For people with severe schizophrenia, who are discharged from a stay in the hospital, these services are often brought together in an integrated approach to offer support in the community away from the hospital setting. In addition to medicine management, housing, and finances, assistance is given for more routine matters such as help with shopping and using public transport. This approach is known as assertive community treatment (ACT) and has been shown to achieve positive results in symptoms, social functioning and quality of life. [204] [205] Another more intense approach is known as intensive care management (ICM). ICM is a stage further than ACT and emphasises support of high intensity in smaller caseloads, (less than twenty). This approach is to provide long-term care in the community. Studies show that ICM improves many of the relevant outcomes including social functioning. [206]

Some studies have shown little evidence for the effectiveness of CBT in either reducing symptoms or preventing relapse. [207] [208] However, other studies have found that CBT does improve overall psychotic symptoms (when in use with medication) and it has been recommended in Canada, but has been seen to have no effect on social function, relapse, or quality of life. [209] In the UK it is recommended as an add-on therapy in the treatment of schizophrenia. [185] [208] Arts therapies are seen to improve negative symptoms in some people, and are recommended by NICE in the UK. [185] This approach is criticised as having not been well-researched, [210] [211] and arts therapies are not recommended in Australian guidelines for example. [212] Peer support, in which people with personal experience of schizophrenia, provide help to each other, is of unclear benefit. [213]


Exercise including aerobic exercise has been shown to improve positive and negative symptoms, cognition, working memory, and improve quality of life. [214] [215] Exercise has also been shown to increase the volume of the hippocampus in those with schizophrenia. A decrease in hippocampal volume is one of the factors linked to the development of the disease. [214] However, there still remains the problem of increasing motivation for, and maintaining participation in physical activity. [216] Supervised sessions are recommended. [215] In the UK healthy eating advice is offered alongside exercise programs. [217]

An inadequate diet is often found in schizophrenia, and associated vitamin deficiencies including those of folate, and vitamin D are linked to the risk factors for the development of schizophrenia and for early death including heart disease. [218] [219] Those with schizophrenia possibly have the worst diet of all the mental disorders. Lower levels of folate and vitamin D have been noted as significantly lower in first episode psychosis. [218] The use of supplemental folate is recommended. [220] A zinc deficiency has also been noted. [221] Vitamin B12 is also often deficient and this is linked to worse symptoms. Supplementation with B vitamins has been shown to significantly improve symptoms, and to put in reverse some of the cognitive deficits. [218] It is also suggested that the noted dysfunction in gut microbiota might benefit from the use of probiotics. [221]


Disability-adjusted life years lost due to schizophrenia per 100,000 inhabitants in 2004
.mw-parser-output .col-begin{border-collapse:collapse;padding:0;color:inherit;width:100%;border:0;margin:0}.mw-parser-output .col-begin-small{font-size:90%}.mw-parser-output .col-break{vertical-align:top;text-align:left}.mw-parser-output .col-break-2{width:50%}.mw-parser-output .col-break-3{width:33.3%}.mw-parser-output .col-break-4{width:25%}.mw-parser-output .col-break-5{width:20%}@media(max-width:720px){.mw-parser-output .col-begin,.mw-parser-output .col-begin>tbody,.mw-parser-output .col-begin>tbody>tr,.mw-parser-output .col-begin>tbody>tr>td{display:block!important;width:100%!important}.mw-parser-output .col-break{padding-left:0!important}}
no data
<= 185
>= 295 Schizophrenia world map - DALY - WHO2004.svg
Disability-adjusted life years lost due to schizophrenia per 100,000 inhabitants in 2004

Schizophrenia has great human and economic costs. [7] It decreases life expectancy by between 20 [13] and 28 years. [14] This is primarily because of its association with heart disease, [222] diabetes, [14] obesity, poor diet, a sedentary lifestyle, and smoking, with an increased rate of suicide playing a lesser role. [13] [223] Side effects of antipsychotics may also increase the risk. [13]

Almost 40% of those with schizophrenia die from complications of cardiovascular disease which is seen to be increasingly associated. [219] An underlying factor of sudden cardiac death may be Brugada syndrome (BrS) – BrS mutations that overlap with those linked with schizophrenia are the calcium channel mutations. [219] BrS may also be drug-induced from certain antipsychotics and antidepressants. [219] Primary polydipsia, or excessive fluid intake, is relatively common in people with chronic schizophrenia. [224] [225] This may lead to hyponatremia which can be life-threatening. Antipsychotics can lead to a dry mouth, but there are several other factors that may contribute to the disorder; it may reduce life expectancy by 13 percent. [225] Barriers to improving the mortality rate in schizophrenia are poverty, overlooking the symptoms of other illnesses, stress, stigma, and medication side effects. [226]

Schizophrenia is a major cause of disability. In 2016, it was classed as the 12th most disabling condition. [227] Approximately 75% of people with schizophrenia have ongoing disability with relapses. [228] Some people do recover completely and others function well in society. [229] Most people with schizophrenia live independently with community support. [27] About 85% are unemployed. [7] In people with a first episode of psychosis in schizophrenia a good long-term outcome occurs in 31%, an intermediate outcome in 42% and a poor outcome in 31%. [230] Males are affected more often than females, and have a worse outcome. [231] Studies showing that outcomes for schizophrenia appear better in the developing than the developed world [232] have been questioned. [233] Social problems, such as long-term unemployment, poverty, homelessness, exploitation, stigmatization and victimization are common consequences, and lead to social exclusion. [25] [26]

There is a higher than average suicide rate associated with schizophrenia estimated at 5% to 6%, most often occurring in the period following onset or first hospital admission. [18] [28] Several times more (20 to 40%) attempt suicide at least once. [10] [100] There are a variety of risk factors, including male sex, depression, a high IQ, [234] heavy smoking, [235] and substance use. [119] Repeated relapse is linked to an increased risk of suicidal behavior. [180] The use of clozapine can reduce the risk of suicide, and of aggression. [236]

A strong association between schizophrenia and tobacco smoking has been shown in worldwide studies. [237] [238] Smoking is especially high in those diagnosed with schizophrenia, with estimates ranging from 80 to 90% being regular smokers, as compared to 20% of the general population. [238] Those who smoke tend to smoke heavily, and additionally smoke cigarettes with high nicotine content. [40] Some propose that this is in an effort to improve symptoms. [239] Among people with schizophrenia use of cannabis is also common. [119]

Schizophrenia leads to an increased risk of dementia. [240]


Most people with schizophrenia are not aggressive, and are more likely to be victims of violence rather than perpetrators. [10] People with schizophrenia are commonly exploited and victimized by violent crime as part of a broader dynamic of social exclusion. [25] [26] People diagnosed with schizophrenia are also subject to forced drug injections, seclusion, and restraint at high rates. [31] [32]

The risk of violence by people with schizophrenia is small. There are minor subgroups where the risk is high. [165] This risk is usually associated with a comorbid disorder such as a substance use disorder – in particular alcohol, or with antisocial personality disorder. [165] Substance use disorder is strongly linked, and other risk factors are linked to deficits in cognition and social cognition including facial perception and insight that are in part included in theory of mind impairments. [241] [242] Poor cognitive functioning, decision-making, and facial perception may contribute to making a wrong judgement of a situation that could result in an inappropriate response such as violence. [243] These associated risk factors are also present in antisocial personality disorder which when present as a comorbid disorder greatly increases the risk of violence. [244] [245]


Deaths per million persons due to schizophrenia in 2012
.mw-parser-output .div-col{margin-top:0.3em;column-width:30em}.mw-parser-output .div-col-small{font-size:90%}.mw-parser-output .div-col-rules{column-rule:1px solid #aaa}.mw-parser-output .div-col dl,.mw-parser-output .div-col ol,.mw-parser-output .div-col ul{margin-top:0}.mw-parser-output .div-col li,.mw-parser-output .div-col dd{page-break-inside:avoid;break-inside:avoid-column}
7-20 Schizophrenia world map-Deaths per million persons-WHO2012.svg
Deaths per million persons due to schizophrenia in 2012

In 2017,[ needs update ] the Global Burden of Disease Study estimated there were 1.1 million new cases; [20] in 2022 the World Health Organization (WHO) reported a total of 24 million cases globally. [2] Schizophrenia affects around 0.3–0.7% of people at some point in their life. [19] [14] In areas of conflict this figure can rise to between 4.0 and 6.5%. [246] It occurs 1.4 times more frequently in males than females and typically appears earlier in men. [86]

Worldwide, schizophrenia is the most common psychotic disorder. [55] The frequency of schizophrenia varies across the world, [10] within countries, [247] and at the local and neighborhood level; [248] this variation in prevalence between studies over time, across geographical locations, and by gender is as high as fivefold. [7]

Schizophrenia causes approximately one percent of worldwide disability adjusted life years [ needs update ] [86] and resulted in 17,000 deaths in 2015. [16]

In 2000,[ needs update ] WHO found the percentage of people affected and the number of new cases that develop each year is roughly similar around the world, with age-standardized prevalence per 100,000 ranging from 343 in Africa to 544 in Japan and Oceania for men, and from 378 in Africa to 527 in Southeastern Europe for women. [249]


Conceptual development

The term "schizophrenia" was coined by Eugen Bleuler. Eugen bleuler.jpg
The term "schizophrenia" was coined by Eugen Bleuler.

Accounts of a schizophrenia-like syndrome are rare in records before the 19th century; the earliest case reports were in 1797 and 1809. [250] Dementia praecox , meaning premature dementia, was used by German psychiatrist Heinrich Schüle in 1886, and then in 1891 by Arnold Pick in a case report of hebephrenia. In 1893 Emil Kraepelin used the term in making a distinction, known as the Kraepelinian dichotomy, between the two psychoses – dementia praecox, and manic depression (now called bipolar disorder). [13] When it became evident that the disorder was not a degenerative dementia, it was renamed schizophrenia by Eugen Bleuler in 1908. [251]

The word schizophrenia translates as 'splitting of the mind' and is Modern Latin from the Greek words schizein (Ancient Greek : σχίζειν, lit. 'to split') and phrēn, (Ancient Greek : φρήν, lit. 'mind') [252] Its use was intended to describe the separation of function between personality, thinking, memory, and perception. [251]

In the early 20th century, the psychiatrist Kurt Schneider categorized the psychotic symptoms of schizophrenia into two groups – hallucinations and delusions. The hallucinations were listed as specific to auditory and the delusions included thought disorders. These were seen as important symptoms, termed first-rank. The most common first-rank symptom was found to belong to thought disorders.[ page needed ] [253] [ page needed ] [254] In 2013 the first-rank symptoms were excluded from the DSM-5 criteria; [255] while they may not be useful in diagnosing schizophrenia, they can assist in differential diagnosis. [256]

Subtypes of schizophrenia – classified as paranoid, disorganized, catatonic, undifferentiated, and residual – were difficult to distinguish and are no longer recognized as separate conditions by DSM-5 (2013) or ICD-11. [257] [258] [259]

Breadth of diagnosis

Before the 1960s, nonviolent petty criminals and women were sometimes diagnosed with schizophrenia, categorizing the latter as ill for not performing their duties within patriarchy as wives and mothers. [260] In the mid-to-late 1960s, black men were categorized as "hostile and aggressive" and diagnosed as schizophrenic at much higher rates, their civil rights and Black Power activism labeled as delusions. [260] [261]

In the early 1970s in the US, the diagnostic model for schizophrenia was broad and clinically based using DSM II. Schizophrenia was diagnosed far more in the US than in Europe which used the ICD-9 criteria. The US model was criticised for failing to demarcate clearly those people with a mental illness. In 1980 DSM III was published and showed a shift in focus from the clinically based biopsychosocial model to a reason-based medical model. [262] DSM IV brought an increased focus on an evidence-based medical model. [263]

Historical treatment

A molecule of chlorpromazine, the first antipsychotic developed in the 1950s Chlorpromazine-3D-vdW.png
A molecule of chlorpromazine, the first antipsychotic developed in the 1950s

In the 1930s a number of shock procedures which induced seizures (convulsions) or comas were used to treat schizophrenia. [264] Insulin shock involved injecting large doses of insulin to induce comas, which in turn produced hypoglycemia and convulsions. [264] [265] The use of electricity to induce seizures was in use as electroconvulsive therapy (ECT) by 1938. [266]

Psychosurgery, including the lobotomy and frontal lobotomy – carried out from the 1930s until the 1970s in the United States, and until the 1980s in France – are recognized as a human rights abuse. [267] [268] In the mid-1950s the first typical antipsychotic, chlorpromazine, was introduced, [269] followed in the 1970s by the first atypical antipsychotic, clozapine. [270]

Political abuse

From the 1960s until 1989, psychiatrists in the USSR and Eastern Bloc diagnosed thousands of people with sluggish schizophrenia, [271] [272] without signs of psychosis, based on "the assumption that symptoms would later appear". [273] Now discredited, the diagnosis provided a convenient way to confine political dissidents. [274]

Society and culture

In the United States, the annual cost of schizophrenia – including direct costs (outpatient, inpatient, drugs, and long-term care) and non-healthcare costs (law enforcement, reduced workplace productivity, and unemployment) – was estimated at $62.7 billion for the year 2002. [275] [lower-alpha 1] In the UK the cost in 2016 was put at £11.8 billion per year with a third of that figure directly attributable to the cost of hospital, social care and treatment. [7]


John Nash, an American mathematician and joint recipient of the 1994 Nobel Memorial Prize in Economic Sciences, had schizophrenia. His life was the subject of the 1998 book, A Beautiful Mind, by Sylvia Nasar. John Forbes Nash, Jr. by Peter Badge.jpg
John Nash, an American mathematician and joint recipient of the 1994 Nobel Memorial Prize in Economic Sciences, had schizophrenia. His life was the subject of the 1998 book, A Beautiful Mind , by Sylvia Nasar.

In 2002, the term for schizophrenia in Japan was changed from seishin-bunretsu-byō (精神分裂病, lit. 'mind-split disease') to tōgō-shitchō-shō (統合失調症, lit. 'integration–dysregulation syndrome') to reduce stigma. [278] The new name, also interpreted as "integration disorder", was inspired by the biopsychosocial model. [279] A similar change was made in South Korea in 2012 to attunement disorder. [280]

Cultural depictions

Media coverage, especially movies, reinforce the public perception of an association between schizophrenia and violence. [281] A majority of movies have historically depicted characters with schizophrenia as criminal, dangerous, violent, unpredictable and homicidal, and depicted delusions and hallucinations as the main symptoms of schizophrenic characters, ignoring other common symptoms, [282] furthering stereotypes of schizophrenia including the idea of a split personality. [283]

The book A Beautiful Mind chronicled the life of John Forbes Nash who had been diagnosed with schizophrenia and won the Nobel Memorial Prize in Economic Sciences. The book was made into a film with the same name; an earlier documentary film was A Brilliant Madness .

In the UK, guidelines for reporting conditions and award campaigns have shown a reduction in negative reporting since 2013. [284]

In 1964 a case study of three males diagnosed with schizophrenia who each had the delusional belief that they were Jesus Christ was published as The Three Christs of Ypsilanti ; a film with the title Three Christs was released in 2020. [285] [286]

Research directions

A 2015 Cochrane review found unclear evidence of benefit from brain stimulation techniques to treat the positive symptoms of schizophrenia, in particular auditory verbal hallucinations (AVHs). [287] Most studies focus on transcranial direct-current stimulation (tDCM), and repetitive transcranial magnetic stimulation (rTMS). [288] Techniques based on focused ultrasound for deep brain stimulation could provide insight for the treatment of AVHs. [288]

The study of potential biomarkers that would help in diagnosis and treatment of schizophrenia is an active area of research as of 2020. Possible biomarkers include markers of inflammation, [99] neuroimaging, [289] brain-derived neurotrophic factor (BDNF), [290] and speech analysis. Some markers such as C-reactive protein are useful in detecting levels of inflammation implicated in some psychiatric disorders but they are not disorder-specific. Other inflammatory cytokines are found to be elevated in first episode psychosis and acute relapse that are normalized after treatment with antipsychotics, and these may be considered as state markers. [291] Deficits in sleep spindles in schizophrenia may serve as a marker of an impaired thalamocortical circuit, and a mechanism for memory impairment. [167] MicroRNAs are highly influential in early neuronal development, and their disruption is implicated in several CNS disorders; circulating microRNAs (cimiRNAs) are found in body fluids such as blood and cerebrospinal fluid, and changes in their levels are seen to relate to changes in microRNA levels in specific regions of brain tissue. These studies suggest that cimiRNAs have the potential to be early and accurate biomarkers in a number of disorders including schizophrenia. [292] [293]

Explanatory notes

  1. A 2007 review stated that the 2002 estimate was still the best available, [276] and a 2018 review cited the same $62.7 billion. [277]

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

<span class="mw-page-title-main">Catatonia</span> Psychiatric behavioural syndrome

Catatonia is a complex neuropsychiatric behavioral syndrome that is characterized by abnormal movements, immobility, abnormal behaviors, and withdrawal. The onset of catatonia can be acute or subtle and symptoms can wax, wane, or change during episodes. It has historically been related to schizophrenia, but catatonia is most often seen in mood disorders. It is now known that catatonic symptoms are nonspecific and may be observed in other mental, neurological, and medical conditions. Catatonia is now a stand-alone diagnosis, and the term is used to describe a feature of the underlying disorder.

Psychosis is a condition of the mind or psyche that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.

<span class="mw-page-title-main">Clozapine</span> Atypical antipsychotic medication

Clozapine is a psychiatric medication and was the first atypical antipsychotic to be discovered. It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics, or who have been unable to tolerate other drugs due to extrapyramidal side effects. It is also used for the treatment of psychosis in Parkinson's disease.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

Schizoaffective disorder is a mental disorder characterized by abnormal thought processes and an unstable mood. This diagnosis requires symptoms of both schizophrenia (psychosis) and a mood disorder: either bipolar disorder or depression. The main criterion is the presence of psychotic symptoms for at least two weeks without any mood symptoms. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. This is a problem as treatment and prognosis differ greatly for most of these diagnoses. many people with schizoaffective disorder have other mental disorder including anxiety disorders

<span class="mw-page-title-main">Thought disorder</span> Disorder of thought form, content or stream

A thought disorder (TD) is a disturbance in cognition which affects language, thought and communication. Psychiatric and psychological glossaries in 2015 and 2017 identified thought disorders as encompassing poverty of ideas, neologisms, paralogia, word salad, and delusions—all disturbances of thought content and form. Two specific terms have been suggested—content thought disorder (CTD) and formal thought disorder (FTD). CTD has been defined as a thought disturbance characterized by multiple fragmented delusions, and the term thought disorder is often used to refer to an FTD: a disruption of the form of thought. Also known as disorganized thinking, FTD results in disorganized speech and is recognized as a major feature of schizophrenia and other psychoses. Disorganized speech leads to an inference of disorganized thought. Thought disorders include derailment, pressured speech, poverty of speech, tangentiality, verbigeration, and thought blocking. One of the first known cases of thought disorders, or specifically OCD as it is known today, was in 1691. John Moore, who was a bishop, had a speech in front of Queen Mary II, about "religious melancholy."

Avolition or amotivation as a symptom of various forms of psychopathology, is the decrease in the ability to initiate and persist in self-directed purposeful activities. Such activities that appear to be neglected usually include routine activities, including hobbies, going to work or school, and most notably, engaging in social activities. A person experiencing avolition may stay at home for long periods of time, rather than seeking out work or peer relations.

Schizotypal personality disorder, also known as schizotypal disorder, is a cluster A personality disorder. The Diagnostic and Statistical Manual of Mental Disorders (DSM) classification describes the disorder specifically as a personality disorder characterized by thought disorder, paranoia, a characteristic form of social anxiety, derealization, transient psychosis, and unconventional beliefs. People with this disorder feel pronounced discomfort in forming and maintaining social connections with other people, primarily due to the belief that other people harbor negative thoughts and views about them. Peculiar speech mannerisms and socially unexpected modes of dress are also characteristic. Schizotypal people may react oddly in conversations, not respond, or talk to themselves. They frequently interpret situations as being strange or having unusual meanings for them; paranormal and superstitious beliefs are common. Schizotypal people usually disagree with the suggestion that their thoughts and behaviors are a 'disorder' and seek medical attention for depression or anxiety instead. Schizotypal personality disorder occurs in approximately 3% of the general population and is more commonly diagnosed in males.

<span class="mw-page-title-main">Psychological intervention</span>

In applied psychology, interventions are actions performed to bring about change in people. A wide range of intervention strategies exist and they are directed towards various types of issues. Most generally, it means any activities used to modify behavior, emotional state, or feelings. Psychological interventions have many different applications and the most common use is for the treatment of mental disorders, most commonly using psychotherapy. The ultimate goal behind these interventions is not only to alleviate symptoms but also to target the root cause of mental disorders.

Schizophrenia is a neurodevelopmental disorder with no precise or single cause. Schizophrenia is thought to arise from multiple mechanisms and complex gene–environment interactions with vulnerability factors. Risk factors of schizophrenia have been identified and include genetic factors, environmental factors such as experiences in life and exposures in a person's environment, and also the function of a person's brain at it develops. The interactions of these risk factors are intricate, as numerous and diverse medical insults from conception to adulthood can be involved. Many theories have been proposed including the combination of genetic and environmental factors may lead to deficits in the neural circuits that affect sensory input and cognitive functions.

The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity.

In medicine, a prodrome is an early sign or symptom that often indicates the onset of a disease before more diagnostically specific signs and symptoms develop. More specifically, it refers to the period between the first recognition of a disease's symptom until it reaches its more severe form. It is derived from the Greek word prodromos, meaning "running before". Prodromes may be non-specific symptoms or, in a few instances, may clearly indicate a particular disease, such as the prodromal migraine aura.

<span class="mw-page-title-main">Persecutory delusion</span> Delusion involving perception of persecution

A persecutory delusion is a type of delusional condition in which the affected person believes that harm is going to occur to oneself by a persecutor, despite a clear lack of evidence. The person may believe that they are being targeted by an individual or a group of people. Persecution delusions are very diverse in terms of content and vary from the possible, although improbable, to the completely bizarre. The delusion can be found in various disorders, being more usual in psychotic disorders.

Childhood schizophrenia is similar in characteristics of schizophrenia that develops at a later age, but has an onset before the age of 13 years, and is more difficult to diagnose. Schizophrenia is characterized by positive symptoms that can include hallucinations, delusions, and disorganized speech; negative symptoms, such as blunted affect and avolition and apathy, and a number of cognitive impairments. Differential diagnosis is problematic since several other neurodevelopmental disorders, including autism spectrum disorder, language disorder, and attention deficit hyperactivity disorder, also have signs and symptoms similar to childhood-onset schizophrenia.

<span class="mw-page-title-main">Prognosis of schizophrenia</span>

The prognosis of schizophrenia is varied at the individual level. In general it has great human and economics costs. It results in a decreased life expectancy of 12–15 years primarily due to its association with obesity, little exercise, and smoking, while an increased rate of suicide plays a lesser role. These differences in life expectancy increased between the 1970s and 1990s, and between the 1990s and 2000s. This difference has not substantially changed in Finland for example – where there is a health system with open access to care.

The diagnosis of schizophrenia, a psychotic disorder, is based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or the World Health Organization's International Classification of Diseases (ICD). Clinical assessment of schizophrenia is carried out by a mental health professional based on observed behavior, reported experiences, and reports of others familiar with the person. Diagnosis is usually made by a psychiatrist. Associated symptoms occur along a continuum in the population and must reach a certain severity and level of impairment before a diagnosis is made. Schizophrenia has a prevalence rate of 0.3-0.7% in the United States.

<span class="mw-page-title-main">Imprinted brain hypothesis</span> Conjecture on the causes of autism and psychosis

The imprinted brain hypothesis is an unsubstantiated hypothesis in evolutionary psychology regarding the causes of autism spectrum and schizophrenia spectrum disorders, first presented by Bernard Crespi and Christopher Badcock in 2008. It claims that certain autistic and schizotypal traits are opposites, and that this implies the etiology of the two conditions must be at odds.

Sex differences in schizophrenia are widely reported. Men and women exhibit different rates of incidence and prevalence, age at onset, symptom expression, course of illness, and response to treatment. Reviews of the literature suggest that understanding the implications of sex differences on schizophrenia may help inform individualized treatment and positively affect outcomes.

<span class="mw-page-title-main">Basic symptoms of schizophrenia</span> Subjective symptoms of schizophrenia

Basic symptoms of schizophrenia are subjective symptoms, described as experienced from a person's perspective, which show evidence of underlying psychopathology. Basic symptoms have generally been applied to the assessment of people who may be at risk to develop psychosis. Though basic symptoms are often disturbing for the person, problems generally do not become evident to others until the person is no longer able to cope with their basic symptoms. Basic symptoms are more specific to identifying people who exhibit signs of prodromal psychosis (prodrome) and are more likely to develop schizophrenia over other disorders related to psychosis. Schizophrenia is a psychotic disorder, but is not synonymous with psychosis. In the prodrome to psychosis, uncharacteristic basic symptoms develop first, followed by more characteristic basic symptoms and brief and self-limited psychotic-like symptoms, and finally the onset of psychosis. People who were assessed to be high risk according to the basic symptoms criteria have a 48.5% likelihood of progressing to psychosis. In 2015, the European Psychiatric Association issued guidance recommending the use of a subscale of basic symptoms, called the Cognitive Disturbances scale (COGDIS), in the assessment of psychosis risk in help-seeking psychiatric patients; in a meta-analysis, COGDIS was shown to be as predictive of transition to psychosis as the Ultra High Risk (UHR) criteria up to 2 years after assessment, and significantly more predictive thereafter. The basic symptoms measured by COGDIS, as well as those measured by another subscale, the Cognitive-Perceptive basic symptoms scale (COPER), are predictive of transition to schizophrenia.


  1. Jones D (2003) [1917]. Roach P, Hartmann J, Setter J (eds.). English Pronouncing Dictionary. Cambridge University Press. ISBN   978-3-12-539683-8.
  2. 1 2 3 4 5 "Schizophrenia Fact sheet". World Health Organization. 10 January 2022. Retrieved 23 August 2022.
  3. 1 2 3 4 5 6 7 "Schizophrenia". Health topics. US National Institute of Mental Health. April 2022. Retrieved 22 August 2022.
  4. "Medicinal treatment of psychosis/schizophrenia". Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). 21 November 2012. Archived from the original on 29 June 2017. Retrieved 26 June 2017.
  5. Proietto Sr J (November 2004). "Diabetes and Antipsychotic Drugs". Medsafe.
  6. Holt RI (September 2019). "Association Between Antipsychotic Medication Use and Diabetes". Current Diabetes Reports. 19 (10). National Center for Biotechnology Information: 96. doi:10.1007/s11892-019-1220-8. PMC   6718373 . PMID   31478094.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Owen MJ, Sawa A, Mortensen PB (July 2016). "Schizophrenia". The Lancet. 388 (10039): 86–97. doi:10.1016/S0140-6736(15)01121-6. PMC   4940219 . PMID   26777917.
  8. Miller B (2 February 2020). "Drug Psychosis May Pull the Schizophrenia Trigger". Psychiatric Times.
  9. Gruebner O, Rapp MA, Adli M, Kluge U, Galea S, Heinz A (February 2017). "Cities and Mental Health". Deutsches Arzteblatt International. 114 (8): 121–127. doi:10.3238/arztebl.2017.0121. PMC   5374256 . PMID   28302261.
  10. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th ed.). Arlington, VA: American Psychiatric Association. 2013. pp. 99–105. ISBN   978-0-89042-555-8.
  11. 1 2 Ferri FF (2010). "Chapter S". Ferri's differential diagnosis: a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia: Elsevier/Mosby. ISBN   978-0-323-07699-9.
  12. 1 2 Paris J (December 2018). "Differential Diagnosis of Borderline Personality Disorder". The Psychiatric Clinics of North America. 41 (4): 575–582. doi:10.1016/j.psc.2018.07.001. PMID   30447725. S2CID   53951650.
  13. 1 2 3 4 5 6 Laursen TM, Nordentoft M, Mortensen PB (2014). "Excess early mortality in schizophrenia". Annual Review of Clinical Psychology. 10: 425–448. doi: 10.1146/annurev-clinpsy-032813-153657 . PMID   24313570.
  14. 1 2 3 4 5 "Schizophrenia". Statistics. US National Institute of Mental Health (NIMH). 22 April 2022. Retrieved 23 August 2022.
  15. "Schizophrenia Fact Sheet and Information". World Health Organization.
  16. 1 2 3 Wang H, Naghavi M, Allen C, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC   5388903 . PMID   27733281.
  17. "ICD-11: 6A20 Schizophrenia". World Health Organization . Retrieved 23 August 2022.
  18. 1 2 3 4 Ferri FF (2019). Ferri's clinical advisor 2019: 5 books in 1. Elsevier. pp. 1225–1226. ISBN   9780323530422.
  19. 1 2 Javitt DC (June 2014). "Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview". The American Journal of Managed Care. 20 (8 Suppl): S160-165. PMID   25180705.
  20. 1 2 James SL, Abate D (November 2018). "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017". The Lancet. 392 (10159): 1789–1858. doi:10.1016/S0140-6736(18)32279-7. PMC   6227754 . PMID   30496104.
  21. 1 2 3 van de Leemput J, Hess JL, Glatt SJ, Tsuang MT (2016). Genetics of Schizophrenia: Historical Insights and Prevailing Evidence. Advances in Genetics. Vol. 96. pp. 99–141. doi:10.1016/bs.adgen.2016.08.001. ISBN   978-0-12-809672-7. PMID   27968732.
  22. 1 2 Parakh P, Basu D (August 2013). "Cannabis and psychosis: have we found the missing links?". Asian Journal of Psychiatry (Review). 6 (4): 281–287. doi:10.1016/j.ajp.2013.03.012. PMID   23810133. Cannabis acts as a component cause of psychosis, that is, it increases the risk of psychosis in people with certain genetic or environmental vulnerabilities, though by itself, it is neither a sufficient nor a necessary cause of psychosis.
  23. 1 2 Vita A, Barlati S (May 2018). "Recovery from schizophrenia: is it possible?". Current Opinion in Psychiatry. 31 (3): 246–255. doi:10.1097/YCO.0000000000000407. PMID   29474266. S2CID   35299996.
  24. Lawrence RE, First MB, Lieberman JA (2015). "Chapter 48: Schizophrenia and Other Psychoses". In Tasman A, Kay J, Lieberman JA, First MB, Riba MB (eds.). Psychiatry (fourth ed.). John Wiley & Sons, Ltd. pp. 798, 816, 819. doi:10.1002/9781118753378.ch48. ISBN   978-1-118-84547-9.
  25. 1 2 3 4 5 Killaspy H (September 2014). "Contemporary mental health rehabilitation". East Asian Archives of Psychiatry. 24 (3): 89–94. PMID   25316799.
  26. 1 2 3 Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. (October 2018). "Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016". Schizophrenia Bulletin. 44 (6): 1195–1203. doi:10.1093/schbul/sby058. PMC   6192504 . PMID   29762765.
  27. 1 2 3 4 5 6 van Os J, Kapur S (August 2009). "Schizophrenia" (PDF). Lancet. 374 (9690): 635–645. doi:10.1016/S0140-6736(09)60995-8. PMID   19700006. S2CID   208792724. Archived from the original (PDF) on 23 June 2013. Retrieved 23 December 2011.
  28. 1 2 Hor K, Taylor M (November 2010). "Suicide and schizophrenia: a systematic review of rates and risk factors". Journal of Psychopharmacology. 24 (4 Suppl): 81–90. doi:10.1177/1359786810385490. PMC   2951591 . PMID   20923923.
  29. 1 2 Siskind D, Siskind V, Kisely S (November 2017). "Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis". Canadian Journal of Psychiatry. 62 (11): 772–777. doi:10.1177/0706743717718167. PMC   5697625 . PMID   28655284.
  30. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID   23810019. S2CID   32085212.
  31. 1 2 Becker T, Kilian R (2006). "Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?". Acta Psychiatrica Scandinavica. Supplementum. 113 (429): 9–16. doi:10.1111/j.1600-0447.2005.00711.x. PMID   16445476. S2CID   34615961.
  32. 1 2 3 Capdevielle D, Boulenger JP, Villebrun D, Ritchie K (September 2009). "Durées d'hospitalisation des patients souffrant de schizophrénie: implication des systèmes de soin et conséquences médicoéconomiques" [Schizophrenic patients' length of stay: mental health care implication and medicoeconomic consequences]. L'Encéphale (in French). 35 (4): 394–399. doi:10.1016/j.encep.2008.11.005. PMID   19748377.
  33. 1 2 Narayan KK, Kumar DS (January 2012). "Disability in a Group of Long-stay Patients with Schizophrenia: Experience from a Mental Hospital". Indian Journal of Psychological Medicine. 34 (1): 70–75. doi: 10.4103/0253-7176.96164 . PMC   3361848 . PMID   22661812.
  34. 1 2 3 "Psychosis and schizophrenia in adults: treatment and management" (PDF). National Institute for Health and Care Excellence (NICE). March 2014. pp. 4–34. Archived from the original (PDF) on 20 April 2014. Retrieved 19 April 2014.
  35. Stępnicki P, Kondej M, Kaczor AA (20 August 2018). "Current Concepts and Treatments of Schizophrenia". Molecules. 23 (8): 2087. doi: 10.3390/molecules23082087 . PMC   6222385 . PMID   30127324.
  36. 1 2 3 4 "RAISE Questions and Answers". US National Institute of Mental Health . Retrieved 29 December 2019.
  37. Marshall M (September 2005). "Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review". Archives of General Psychiatry. 62 (9): 975–983. doi:10.1001/archpsyc.62.9.975. PMID   16143729. S2CID   13504781.
  38. 1 2 Montagnese M, Leptourgos P, Fernyhough C, et al. (January 2021). "A Review of Multimodal Hallucinations: Categorization, Assessment, Theoretical Perspectives, and Clinical Recommendations". Schizophr Bull. 47 (1): 237–248. doi:10.1093/schbul/sbaa101. PMC   7825001 . PMID   32772114.
  39. Császár N, Kapócs G, Bókkon I (27 May 2019). "A possible key role of vision in the development of schizophrenia". Reviews in the Neurosciences. 30 (4): 359–379. doi:10.1515/revneuro-2018-0022. PMID   30244235. S2CID   52813070.
  40. 1 2 American Psychiatric Association. Task Force on DSM-IV. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Pub. pp. 299–304. ISBN   978-0-89042-025-6.
  41. 1 2 Heinz A, Voss M, Lawrie SM, Mishara A, Bauer M, Gallinat J, et al. (September 2016). "Shall we really say goodbye to first rank symptoms?". European Psychiatry. 37: 8–13. doi:10.1016/j.eurpsy.2016.04.010. PMID   27429167. S2CID   13761854.
  42. 1 2 Adida M, Azorin JM, Belzeaux R, Fakra E (December 2015). "[Negative Symptoms: Clinical and Psychometric Aspects]". L'Encephale. 41 (6 Suppl 1): 6S15–17. doi:10.1016/S0013-7006(16)30004-5. PMID   26776385.
  43. Mach C, Dollfus S (April 2016). "[Scale for Assessing Negative Symptoms in Schizophrenia: A Systematic Review]". L'Encephale. 42 (2): 165–171. doi:10.1016/j.encep.2015.12.020. PMID   26923997.
  44. Waltz JA, Gold JM (2016). "Motivational Deficits in Schizophrenia and the Representation of Expected Value". Current Topics in Behavioral Neurosciences. 27: 375–410. doi:10.1007/7854_2015_385. ISBN   978-3-319-26933-7. PMC   4792780 . PMID   26370946.
  45. 1 2 Husain M, Roiser JP (August 2018). "Neuroscience of apathy and anhedonia: a transdiagnostic approach". Nature Reviews. Neuroscience. 19 (8): 470–484. doi:10.1038/s41583-018-0029-9. PMID   29946157. S2CID   49428707.
  46. 1 2 Galderisi S, Mucci A, Buchanan RW, Arango C (August 2018). "Negative symptoms of schizophrenia: new developments and unanswered research questions". The Lancet. Psychiatry. 5 (8): 664–677. doi:10.1016/S2215-0366(18)30050-6. PMID   29602739. S2CID   4483198.
  47. Klaus F, Dorsaz O, Kaiser S (19 September 2018). "[Negative symptoms in schizophrenia – overview and practical implications]". Revue médicale suisse. 14 (619): 1660–1664. doi:10.53738/REVMED.2018.14.619.1660. PMID   30230774. S2CID   246764656.
  48. Batinic B (June 2019). "Cognitive Models of Positive and Negative Symptoms of Schizophrenia and Implications for Treatment". Psychiatria Danubina. 31 (Suppl 2): 181–184. PMID   31158119.
  49. Bortolon C, Macgregor A, Capdevielle D, Raffard S (September 2018). "Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies". Neuropsychologia. 118 (Pt B): 22–33. doi:10.1016/j.neuropsychologia.2017.09.033. PMID   28966139. S2CID   13411386.
  50. 1 2 3 4 5 Marder SR, Kirkpatrick B (May 2014). "Defining and measuring negative symptoms of schizophrenia in clinical trials". European Neuropsychopharmacology. 24 (5): 737–743. doi:10.1016/j.euroneuro.2013.10.016. PMID   24275698. S2CID   5172022.
  51. 1 2 3 Tatsumi K, Kirkpatrick B, Strauss GP, Opler M (April 2020). "The brief negative symptom scale in translation: A review of psychometric properties and beyond". European Neuropsychopharmacology. 33: 36–44. doi:10.1016/j.euroneuro.2020.01.018. PMID   32081498. S2CID   211141678.
  52. Klaus F, Kaiser S, Kirschner M (June 2018). "[Negative Symptoms in Schizophrenia – an Overview]". Therapeutische Umschau. 75 (1): 51–56. doi:10.1024/0040-5930/a000966. PMID   29909762. S2CID   196502392.
  53. Wójciak P, Rybakowski J (30 April 2018). "Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia". Psychiatria Polska. 52 (2): 185–197. doi: 10.12740/PP/70610 . PMID   29975360.
  54. 1 2 3 4 5 6 Murante T, Cohen CI (January 2017). "Cognitive Functioning in Older Adults With Schizophrenia". Focus (American Psychiatric Publishing). 15 (1): 26–34. doi:10.1176/appi.focus.20160032. PMC   6519630 . PMID   31975837.
  55. 1 2 Kar SK, Jain M (July 2016). "Current understandings about cognition and the neurobiological correlates in schizophrenia". Journal of Neurosciences in Rural Practice. 7 (3): 412–418. doi: 10.4103/0976-3147.176185 . PMC   4898111 . PMID   27365960.
  56. 1 2 Bozikas VP, Andreou C (February 2011). "Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature". The Australian and New Zealand Journal of Psychiatry. 45 (2): 93–108. doi:10.3109/00048674.2010.541418. PMID   21320033. S2CID   26135485.
  57. Shah JN, Qureshi SU, Jawaid A, Schulz PE (June 2012). "Is there evidence for late cognitive decline in chronic schizophrenia?". The Psychiatric Quarterly. 83 (2): 127–144. doi:10.1007/s11126-011-9189-8. PMID   21863346. S2CID   10970088.
  58. 1 2 3 Biedermann F, Fleischhacker WW (August 2016). "Psychotic disorders in DSM-5 and ICD-11". CNS Spectrums. 21 (4): 349–354. doi:10.1017/S1092852916000316. PMID   27418328. S2CID   24728447.
  59. 1 2 3 Vidailhet P (September 2013). "[First-episode psychosis, cognitive difficulties and remediation]". L'Encéphale (in French). 39 (Suppl 2): S83-92. doi:10.1016/S0013-7006(13)70101-5. PMID   24084427.
  60. 1 2 3 Hashimoto K (5 July 2019). "Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings". Current Psychiatry Reports. 21 (8): 75. doi:10.1007/s11920-019-1063-7. PMID   31278495. S2CID   195814019.
  61. 1 2 3 4 5 6 Green MF, Horan WP, Lee J (June 2019). "Nonsocial and social cognition in schizophrenia: current evidence and future directions". World Psychiatry. 18 (2): 146–161. doi:10.1002/wps.20624. PMC   6502429 . PMID   31059632.
  62. Javitt DC, Sweet RA (September 2015). "Auditory dysfunction in schizophrenia: integrating clinical and basic features". Nature Reviews. Neuroscience. 16 (9): 535–550. doi:10.1038/nrn4002. PMC   4692466 . PMID   26289573.
  63. 1 2 Megreya AM (2016). "Face perception in schizophrenia: a specific deficit". Cognitive Neuropsychiatry. 21 (1): 60–72. doi:10.1080/13546805.2015.1133407. PMID   26816133. S2CID   26125559.
  64. Eack SM (July 2012). "Cognitive remediation: a new generation of psychosocial interventions for people with schizophrenia". Social Work. 57 (3): 235–246. doi:10.1093/sw/sws008. PMC   3683242 . PMID   23252315.
  65. Pomarol-Clotet E, Oh M, Laws KR, McKenna PJ (February 2008). "Semantic priming in schizophrenia: systematic review and meta-analysis". The British Journal of Psychiatry. 192 (2): 92–97. doi: 10.1192/bjp.bp.106.032102 . hdl: 2299/2735 . PMID   18245021.
  66. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD (April 2010). "Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies". Neuropsychopharmacology. 35 (5): 1053–1062. doi:10.1038/npp.2009.211. PMC   3055399 . PMID   20090669.
  67. King DJ, Hodgekins J, Chouinard PA, Chouinard VA, Sperandio I (June 2017). "A review of abnormalities in the perception of visual illusions in schizophrenia". Psychonomic Bulletin and Review. 24 (3): 734–751. doi:10.3758/s13423-016-1168-5. PMC   5486866 . PMID   27730532.
  68. Kohler CG, Walker JB, Martin EA, Healey KM, Moberg PJ (September 2010). "Facial emotion perception in schizophrenia: a meta-analytic review". Schizophrenia Bulletin. 36 (5): 1009–1019. doi:10.1093/schbul/sbn192. PMC   2930336 . PMID   19329561.
  69. Le Gall E, Iakimova G (December 2018). "[Social cognition in schizophrenia and autism spectrum disorder: Points of convergence and functional differences]". L'Encéphale. 44 (6): 523–537. doi:10.1016/j.encep.2018.03.004. PMID   30122298. S2CID   150099236.
  70. Grill-Spector K, Weiner KS, Kay K, Gomez J (September 2017). "The Functional Neuroanatomy of Human Face Perception". Annual Review of Vision Science. 3: 167–196. doi:10.1146/annurev-vision-102016-061214. PMC   6345578 . PMID   28715955.
  71. Fountoulakis KN, Panagiotidis P, Kimiskidis V, Nimatoudis I, Gonda X (February 2019). "Neurological soft signs in familial and sporadic schizophrenia". Psychiatry Research. 272: 222–229. doi:10.1016/j.psychres.2018.12.105. PMID   30590276. S2CID   56476015.
  72. Bourgou Gaha S, Halayem Dhouib S, Amado I, Bouden A (June 2015). "[Neurological soft signs in early onset schizophrenia]". L'Encephale. 41 (3): 209–214. doi:10.1016/j.encep.2014.01.005. PMID   24854724.
  73. 1 2 Da Fonseca D, Fourneret P (December 2018). "[Very early onset schizophrenia]". L'Encephale. 44 (6S): S8–S11. doi:10.1016/S0013-7006(19)30071-5. PMID   30935493. S2CID   150798223.
  74. Häfner H (2019). "From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness". Psychiatry Journal. 2019: 9804836. doi: 10.1155/2019/9804836 . PMC   6500669 . PMID   31139639.
  75. Cohen CI, Freeman K, Ghoneim D, Vengassery A, Ghezelaiagh B, Reinhardt MM (March 2018). "Advances in the Conceptualization and Study of Schizophrenia in Later Life". The Psychiatric Clinics of North America. 41 (1): 39–53. doi:10.1016/j.psc.2017.10.004. PMID   29412847.
  76. 1 2 3 George M, Maheshwari S, Chandran S, Manohar JS, Sathyanarayana Rao TS (October 2017). "Understanding the schizophrenia prodrome". Indian Journal of Psychiatry. 59 (4): 505–509. doi: 10.4103/psychiatry.IndianJPsychiatry_464_17 (inactive 31 January 2024). PMC   5806335 . PMID   29497198.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  77. 1 2 Conroy S, Francis M, Hulvershorn LA (March 2018). "Identifying and treating the prodromal phases of bipolar disorder and schizophrenia". Current Treatment Options in Psychiatry. 5 (1): 113–128. doi:10.1007/s40501-018-0138-0. PMC   6196741 . PMID   30364516.
  78. Lecardeur L, Meunier-Cussac S, Dollfus S (May 2013). "[Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment]". L'Encephale. 39 (Suppl 1): S64-71. doi:10.1016/j.encep.2012.10.011. PMID   23528322.
  79. Mullin AP, Gokhale A, Moreno-De-Luca A, Sanyal S, Waddington JL, Faundez V (December 2013). "Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes". Translational Psychiatry. 3 (12): e329. doi:10.1038/tp.2013.108. PMC   4030327 . PMID   24301647.
  80. 1 2 3 Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, et al. (June 2016). "A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis". Neuroscience and Biobehavioral Reviews. 65: 185–194. doi:10.1016/j.neubiorev.2016.03.017. PMC   4876729 . PMID   27073049.
  81. 1 2 Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N (March 2017). "Theranostic Biomarkers for Schizophrenia". International Journal of Molecular Sciences. 18 (4): 733. doi: 10.3390/ijms18040733 . PMC   5412319 . PMID   28358316.
  82. 1 2 Suvisaari J (2010). "[Risk factors of schizophrenia]". Duodecim; Laaketieteellinen Aikakauskirja (in Finnish). 126 (8): 869–876. PMID   20597333.
  83. 1 2 Combs DR, Mueser KT, Gutierrez MM (2011). "Chapter 8: Schizophrenia: Etiological considerations". In Hersen M, Beidel DC (eds.). Adult psychopathology and diagnosis (6th ed.). John Wiley & Sons. ISBN   978-1-118-13884-7.
  84. O'Donovan MC, Williams NM, Owen MJ (October 2003). "Recent advances in the genetics of schizophrenia". Human Molecular Genetics. 12 Spec No 2: R125–133. doi: 10.1093/hmg/ddg302 . PMID   12952866.
  85. 1 2 Torrey EF, Yolken RH (August 2019). "Schizophrenia as a pseudogenetic disease: A call for more gene-environmental studies". Psychiatry Research. 278: 146–150. doi:10.1016/j.psychres.2019.06.006. PMID   31200193. S2CID   173991937.
  86. 1 2 3 4 5 6 7 8 Picchioni MM, Murray RM (July 2007). "Schizophrenia". BMJ. 335 (7610): 91–95. doi:10.1136/bmj.39227.616447.BE. PMC   1914490 . PMID   17626963.
  87. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O'Donovan MC, et al. (May 2015). "Evaluating historical candidate genes for schizophrenia". Molecular Psychiatry. 20 (5): 555–562. doi:10.1038/mp.2015.16. PMC   4414705 . PMID   25754081.
  88. Schulz SC, Green MF, Nelson KJ (2016). Schizophrenia and Psychotic Spectrum Disorders. Oxford University Press. pp. 124–125. ISBN   9780199378067.
  89. Schork AJ, Wang Y, Thompson WK, Dale AM, Andreassen OA (February 2016). "New statistical approaches exploit the polygenic architecture of schizophrenia—implications for the underlying neurobiology". Current Opinion in Neurobiology. 36: 89–98. doi:10.1016/j.conb.2015.10.008. PMC   5380793 . PMID   26555806.
  90. Coelewij L, Curtis D (2018). "Mini-review: Update on the genetics of schizophrenia". Annals of Human Genetics. 82 (5): 239–243. doi: 10.1111/ahg.12259 . ISSN   0003-4800. PMID   29923609. S2CID   49311660.
  91. Kendler KS (March 2016). "The Schizophrenia Polygenic Risk Score: To What Does It Predispose in Adolescence?". JAMA Psychiatry. 73 (3): 193–194. doi:10.1001/jamapsychiatry.2015.2964. PMID   26817666.
  92. 1 2 Lowther C, Costain G, Baribeau DA, Bassett AS (September 2017). "Genomic Disorders in Psychiatry—What Does the Clinician Need to Know?". Current Psychiatry Reports. 19 (11): 82. doi:10.1007/s11920-017-0831-5. PMID   28929285. S2CID   4776174.
  93. Bundy H, Stahl D, MacCabe JH (February 2011). "A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives: Fertility in schizophrenia". Acta Psychiatrica Scandinavica. 123 (2): 98–106. doi:10.1111/j.1600-0447.2010.01623.x. PMID   20958271. S2CID   45179016.
  94. van Dongen J, Boomsma DI (March 2013). "The evolutionary paradox and the missing heritability of schizophrenia". American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 162 (2): 122–136. doi:10.1002/ajmg.b.32135. PMID   23355297. S2CID   9648115.
  95. Owen MJ, Sawa A, Mortensen PB (2 July 2016). "Schizophrenia". Lancet. 388 (10039): 86–97. doi:10.1016/S0140-6736(15)01121-6. PMC   4940219 . PMID   26777917.
  96. Goh XX, Tang PY, Tee SF (July 2021). "8-Hydroxy-2'-Deoxyguanosine and Reactive Oxygen Species as Biomarkers of Oxidative Stress in Mental Illnesses: A Meta-Analysis". Psychiatry Investig (Meta-analysis). 18 (7): 603–618. doi:10.30773/pi.2020.0417. PMC   8328836 . PMID   34340273.
  97. Stilo SA, Murray RM (14 September 2019). "Non-Genetic Factors in Schizophrenia". Current Psychiatry Reports. 21 (10): 100. doi:10.1007/s11920-019-1091-3. PMC   6745031 . PMID   31522306.
  98. Cirulli F, Musillo C, Berry A (5 February 2020). "Maternal Obesity as a Risk Factor for Brain Development and Mental Health in the Offspring". Neuroscience. 447: 122–135. doi:10.1016/j.neuroscience.2020.01.023. hdl: 11573/1387747 . PMID   32032668. S2CID   211029692.
  99. 1 2 Upthegrove R, Khandaker GM (2020). "Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia" (PDF). Current Topics in Behavioral Neurosciences. 44: 49–66. doi:10.1007/7854_2018_88. ISBN   978-3-030-39140-9. PMID   31115797. S2CID   162169817.
  100. 1 2 Chiang M, Natarajan R, Fan X (February 2016). "Vitamin D in schizophrenia: a clinical review". Evidence-Based Mental Health. 19 (1): 6–9. doi:10.1136/eb-2015-102117. PMC   10699337 . PMID   26767392. S2CID   206926835.
  101. Arias I, Sorlozano A, Villegas E, de Dios Luna J, McKenney K, Cervilla J, et al. (April 2012). "Infectious agents associated with schizophrenia: a meta-analysis". Schizophrenia Research. 136 (1–3): 128–136. doi:10.1016/j.schres.2011.10.026. hdl: 10481/90076 . PMID   22104141. S2CID   2687441.
  102. Yolken R (June 2004). "Viruses and schizophrenia: a focus on herpes simplex virus". Herpes. 11 (Suppl 2): 83A–88A. PMID   15319094.
  103. Khandaker GM (August 2012). "Childhood infection and adult schizophrenia: a meta-analysis of population-based studies". Schizophr. Res. 139 (1–3): 161–168. doi:10.1016/j.schres.2012.05.023. PMC   3485564 . PMID   22704639.
  104. "Correction to: Cat Ownership and Schizophrenia-Related Disorders and Psychotic-Like Experiences: A Systematic Review and Meta-Analysis". Schizophrenia Bulletin. 50 (3): 720–721. April 2024. doi:10.1093/schbul/sbae027. PMC   11059805 . PMID   38491934.
  105. 1 2 Pearce J, Murray C, Larkin W (July 2019). "Childhood adversity and trauma:experiences of professionals trained to routinely enquire about childhood adversity". Heliyon. 5 (7): e01900. Bibcode:2019Heliy...501900P. doi: 10.1016/j.heliyon.2019.e01900 . PMC   6658729 . PMID   31372522.
  106. Dvir Y, Denietolis B, Frazier JA (October 2013). "Childhood trauma and psychosis". Child and Adolescent Psychiatric Clinics of North America. 22 (4): 629–641. doi:10.1016/j.chc.2013.04.006. PMID   24012077. S2CID   40053289.
  107. Misiak B, Krefft M, Bielawski T, Moustafa AA, Sąsiadek MM, Frydecka D (April 2017). "Toward a unified theory of childhood trauma and psychosis: A comprehensive review of epidemiological, clinical, neuropsychological and biological findings". Neuroscience and Biobehavioral Reviews. 75: 393–406. doi:10.1016/j.neubiorev.2017.02.015. PMID   28216171. S2CID   21614845.
  108. 1 2 Nettis MA, Pariante CM, Mondelli V (2020). "Early-Life Adversity, Systemic Inflammation and Comorbid Physical and Psychiatric Illnesses of Adult Life". Current Topics in Behavioral Neurosciences. 44: 207–225. doi:10.1007/7854_2019_89. ISBN   978-3-030-39140-9. PMID   30895531. S2CID   84842249.
  109. Guloksuz S, van Os J (January 2018). "The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum". Psychological Medicine. 48 (2): 229–244. doi: 10.1017/S0033291717001775 . PMID   28689498.
  110. Costa E, Silva JA, Steffen RE (November 2019). "Urban environment and psychiatric disorders: a review of the neuroscience and biology". Metabolism: Clinical and Experimental. 100S: 153940. doi:10.1016/j.metabol.2019.07.004. PMID   31610855. S2CID   204704312.
  111. van Os J (April 2004). "Does the urban environment cause psychosis?". The British Journal of Psychiatry. 184 (4): 287–8. doi: 10.1192/bjp.184.4.287 . PMID   15056569.
  112. Attademo L, Bernardini F, Garinella R, Compton MT (March 2017). "Environmental pollution and risk of psychotic disorders: A review of the science to date". Schizophrenia Research. 181: 55–59. doi:10.1016/j.schres.2016.10.003. PMID   27720315. S2CID   25505446.
  113. Selten JP, Cantor-Graae E, Kahn RS (March 2007). "Migration and schizophrenia". Current Opinion in Psychiatry. 20 (2): 111–115. doi:10.1097/YCO.0b013e328017f68e. PMID   17278906. S2CID   21391349.
  114. Sharma R, Agarwal A, Rohra VK, Assidi M, Abu-Elmagd M, Turki RF (April 2015). "Effects of increased paternal age on sperm quality, reproductive outcome and associated epigenetic risks to offspring". Reproductive Biology and Endocrinology. 13: 35. doi: 10.1186/s12958-015-0028-x . PMC   4455614 . PMID   25928123.
  115. 1 2 Gregg L, Barrowclough C, Haddock G (May 2007). "Reasons for increased substance use in psychosis". Clinical Psychology Review. 27 (4): 494–510. doi:10.1016/j.cpr.2006.09.004. PMID   17240501.
  116. Sagud M, Mihaljević-Peles A, Mück-Seler D, Pivac N, Vuksan-Cusa B, Brataljenović T, et al. (September 2009). "Smoking and schizophrenia". Psychiatria Danubina. 21 (3): 371–375. PMID   19794359.
  117. Larson M (30 March 2006). "Alcohol-Related Psychosis". EMedicine. Archived from the original on 9 November 2008. Retrieved 27 September 2006.
  118. Leweke FM, Koethe D (June 2008). "Cannabis and psychiatric disorders: it is not only addiction". Addiction Biology. 13 (2): 264–75. doi:10.1111/j.1369-1600.2008.00106.x. PMID   18482435. S2CID   205400285.
  119. 1 2 3 4 Khokhar JY, Henricks AM, Sullivan ED, Green AI (2018). "Unique Effects of Clozapine: A Pharmacological Perspective". Apprentices to Genius: A tribute to Solomon H. Snyder. Advances in Pharmacology. Vol. 82. pp. 137–162. doi:10.1016/bs.apha.2017.09.009. ISBN   978-0128140871. PMC   7197512 . PMID   29413518.
  120. Bighelli I, Rodolico A, García-Mieres H, et al. (November 2021). "Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis" (PDF). Lancet Psychiatry. 8 (11): 969–980. doi: 10.1016/S2215-0366(21)00243-1 . PMID   34653393. S2CID   239003358.
  121. Patel S, Khan S, M S, Hamid P (July 2020). "The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review". Cureus . 12 (7): e9309. doi: 10.7759/cureus.9309 . PMC   7442038 . PMID   32839678.
  122. Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, et al. (June 2020). "Cannabis use and psychosis: a review of reviews". Eur Arch Psychiatry Clin Neurosci. 270 (4): 403–412. doi:10.1007/s00406-019-01068-z. PMID   31563981. S2CID   203567900.
  123. "Causes — Schizophrenia". UK National Health Service. 11 November 2019. Retrieved 8 December 2021.
  124. Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L, et al. (November 2018). "Cannabis consumption and psychosis or schizophrenia development". The International Journal of Social Psychiatry. 64 (7): 690–704. doi:10.1177/0020764018801690. PMID   30442059. S2CID   53563635.
  125. Hayes D, Kyriakopoulos M (August 2018). "Dilemmas in the treatment of early-onset first-episode psychosis". Therapeutic Advances in Psychopharmacology. 8 (8): 231–239. doi: 10.1177/2045125318765725 . PMC   6058451 . PMID   30065814.
  126. Cannon TD (December 2015). "How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis". Trends Cogn Sci. 19 (12): 744–756. doi:10.1016/j.tics.2015.09.009. PMC   4673025 . PMID   26493362.
  127. Correll CU, Schooler NR (2020). "Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment". Neuropsychiatric Disease and Treatment. 16: 519–534. doi: 10.2147/NDT.S225643 . PMC   7041437 . PMID   32110026.
  128. Howes OD (1 January 2017). "The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia". Biological Psychiatry. 81 (1): 9–20. doi:10.1016/j.biopsych.2016.07.014. PMC   5675052 . PMID   27720198.
  129. Broyd A, Balzan RP, Woodward TS, Allen P (June 2017). "Dopamine, cognitive biases and assessment of certainty: A neurocognitive model of delusions". Clinical Psychology Review. 54: 96–106. doi:10.1016/j.cpr.2017.04.006. PMID   28448827. S2CID   3729566.
  130. Howes OD, Murray RM (May 2014). "Schizophrenia: an integrated sociodevelopmental-cognitive model". Lancet. 383 (9929): 1677–1687. doi:10.1016/S0140-6736(13)62036-X. PMC   4127444 . PMID   24315522.
  131. Grace AA (August 2016). "Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression". Nature Reviews. Neuroscience. 17 (8): 524–532. doi:10.1038/nrn.2016.57. PMC   5166560 . PMID   27256556.
  132. Fusar-Poli P, Meyer-Lindenberg A (January 2013). "Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies". Schizophrenia Bulletin. 39 (1): 33–42. doi:10.1093/schbul/sbr180. PMC   3523905 . PMID   22282454.
  133. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. (August 2012). "The nature of dopamine dysfunction in schizophrenia and what this means for treatment". Archives of General Psychiatry. 69 (8): 776–786. doi:10.1001/archgenpsychiatry.2012.169. PMC   3730746 . PMID   22474070.
  134. Arnsten AF, Girgis RR, Gray DL, Mailman RB (January 2017). "Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia". Biological Psychiatry. 81 (1): 67–77. doi:10.1016/j.biopsych.2015.12.028. PMC   4949134 . PMID   26946382.
  135. Maia TV, Frank MJ (January 2017). "An Integrative Perspective on the Role of Dopamine in Schizophrenia". Biological Psychiatry. 81 (1): 52–66. doi:10.1016/j.biopsych.2016.05.021. PMC   5486232 . PMID   27452791.
  136. 1 2 Pratt J, Dawson N, Morris BJ, Grent-'t-Jong T, Roux F, Uhlhaas PJ (February 2017). "Thalamo-cortical communication, glutamatergic neurotransmission and neural oscillations: A unique window into the origins of ScZ?" (PDF). Schizophrenia Research. 180: 4–12. doi:10.1016/j.schres.2016.05.013. PMID   27317361. S2CID   205075178.
  137. Catts VS, Lai YL, Weickert CS, Weickert TW, Catts SV (April 2016). "A quantitative review of the post-mortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?". Biological Psychology. 116: 57–67. doi: 10.1016/j.biopsycho.2015.10.013 . PMID   26549579.
  138. Michie PT, Malmierca MS, Harms L, Todd J (April 2016). "The neurobiology of MMN and implications for schizophrenia". Biological Psychology. 116: 90–97. doi:10.1016/j.biopsycho.2016.01.011. PMID   26826620. S2CID   41179430.
  139. 1 2 Marín O (January 2012). "Interneuron dysfunction in psychiatric disorders". Nature Reviews. Neuroscience. 13 (2): 107–120. doi:10.1038/nrn3155. PMID   22251963. S2CID   205507186.
  140. Lewis DA, Hashimoto T, Volk DW (April 2005). "Cortical inhibitory neurons and schizophrenia". Nature Reviews. Neuroscience. 6 (4): 312–324. doi:10.1038/nrn1648. PMID   15803162. S2CID   3335493.
  141. Senkowski D, Gallinat J (June 2015). "Dysfunctional prefrontal gamma-band oscillations reflect working memory and other cognitive deficits in schizophrenia". Biological Psychiatry. 77 (12): 1010–1019. doi:10.1016/j.biopsych.2015.02.034. PMID   25847179. S2CID   206104940. Several studies that investigated perceptual processes found impaired GBR in ScZ patients over sensory areas, such as the auditory and visual cortex. Moreover, studies examining steady-state auditory-evoked potentials showed deficits in the gen- eration of oscillations in the gamma band.
  142. Reilly TJ, Nottage JF, Studerus E, Rutigliano G, Micheli AI, Fusar-Poli P, et al. (July 2018). "Gamma band oscillations in the early phase of psychosis: A systematic review". Neuroscience and Biobehavioral Reviews. 90: 381–399. doi:10.1016/j.neubiorev.2018.04.006. PMID   29656029. S2CID   4891072. Decreased gamma power in response to a task was a relatively consistent finding, with 5 out of 6 studies reported reduced evoked or induced power.
  143. 1 2 Sloan SA, Barres BA (August 2014). "Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders". Curr Opin Neurobiol. 27: 75–81. doi:10.1016/j.conb.2014.03.005. PMC   4433289 . PMID   24694749.
  144. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS (January 2011). "Cognitive control deficits in schizophrenia: mechanisms and meaning". Neuropsychopharmacology. 36 (1): 316–338. doi:10.1038/npp.2010.156. PMC   3052853 . PMID   20844478.
  145. Barch DM, Ceaser A (January 2012). "Cognition in schizophrenia: core psychological and neural mechanisms". Trends in Cognitive Sciences. 16 (1): 27–34. doi:10.1016/j.tics.2011.11.015. PMC   3860986 . PMID   22169777.
  146. Eisenberg DP, Berman KF (January 2010). "Executive function, neural circuitry, and genetic mechanisms in schizophrenia". Neuropsychopharmacology. 35 (1): 258–277. doi:10.1038/npp.2009.111. PMC   2794926 . PMID   19693005.
  147. Walton E, Hibar DP, van Erp TG, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, et al. (May 2017). "Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium". Acta Psychiatrica Scandinavica. 135 (5): 439–447. doi:10.1111/acps.12718. PMC   5399182 . PMID   28369804.
  148. Walton E, Hibar DP, van Erp TG, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, et al. (Karolinska Schizophrenia Project Consortium (KaSP)) (January 2018). "Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium". Psychological Medicine. 48 (1): 82–94. doi:10.1017/S0033291717001283. PMC   5826665 . PMID   28545597.
  149. Cohen AS, Minor KS (January 2010). "Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies". Schizophrenia Bulletin. 36 (1): 143–150. doi:10.1093/schbul/sbn061. PMC   2800132 . PMID   18562345.
  150. Strauss GP, Gold JM (April 2012). "A new perspective on anhedonia in schizophrenia". The American Journal of Psychiatry. 169 (4): 364–373. doi:10.1176/appi.ajp.2011.11030447. PMC   3732829 . PMID   22407079.
  151. Young J, Anticevic A, Barch D (2018). "Cognitive and Motivational Neuroscience of Psychotic Disorders". In Charney D, Buxbaum J, Sklar P, Nestler E (eds.). Charney & Nestler's Neurobiology of Mental Illness (5th ed.). New York: Oxford University Press. pp. 215, 217. ISBN   9780190681425. Several recent reviews (e.g., Cohen and Minor, 2010) have found that individuals with schizophrenia show relatively intact self-reported emotional responses to affect-eliciting stimuli as well as other indicators of intact response(215)...Taken together, the literature increasingly suggests that there may be a deficit in putatively DA-mediated reward learning and/ or reward prediction functions in schizophrenia. Such findings suggest that impairment in striatal reward prediction mechanisms may influence "wanting" in schizophrenia in a way that reduces the ability of individuals with schizophrenia to use anticipated rewards to drive motivated behavior.(217)
  152. 1 2 Wiberg A, Ng M, Al Omran Y, Alfaro-Almagro F, McCarthy P, Marchini J, et al. (October 2019). "Handedness, language areas and neuropsychiatric diseases: insights from brain imaging and genetics". Brain. 142 (10): 2938–2947. doi:10.1093/brain/awz257. PMC   6763735 . PMID   31504236.
  153. Tzourio-Mazoyer N, Kennedy H, Van Essen DC, Christen Y (2016). "Intra- and Inter-hemispheric Connectivity Supporting Hemispheric Specialization". Micro-, Meso- and Macro-Connectomics of the Brain. Research and Perspectives in Neurosciences. pp. 129–146. doi:10.1007/978-3-319-27777-6_9. ISBN   978-3-319-27776-9. PMID   28590670. S2CID   147813648.
  154. Ocklenburg S, Güntürkün O, Hugdahl K, Hirnstein M (December 2015). "Laterality and mental disorders in the postgenomic age--A closer look at schizophrenia and language lateralization". Neuroscience and Biobehavioral Reviews. 59: 100–110. doi:10.1016/j.neubiorev.2015.08.019. PMID   26598216. S2CID   15983622.
  155. Friston KJ, Stephan KE, Montague R, Dolan RJ (July 2014). "Computational psychiatry: the brain as a phantastic organ". The Lancet. Psychiatry. 1 (2): 148–158. doi:10.1016/S2215-0366(14)70275-5. PMID   26360579. S2CID   15504512.
  156. Griffin JD, Fletcher PC (May 2017). "Predictive Processing, Source Monitoring, and Psychosis". Annual Review of Clinical Psychology. 13: 265–289. doi:10.1146/annurev-clinpsy-032816-045145. PMC   5424073 . PMID   28375719.
  157. Fletcher PC, Frith CD (January 2009). "Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia" (PDF). Nature Reviews. Neuroscience. 10 (1): 48–58. doi:10.1038/nrn2536. PMID   19050712. S2CID   6219485.
  158. Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH (November 2010). "Toward a neurobiology of delusions". Progress in Neurobiology. 92 (3): 345–369. doi:10.1016/j.pneurobio.2010.06.007. PMC   3676875 . PMID   20558235.
  159. Bastos AM, Usrey WM, Adams RA, Mangun GR, Fries P, Friston KJ (November 2012). "Canonical microcircuits for predictive coding". Neuron. 76 (4): 695–711. doi:10.1016/j.neuron.2012.10.038. PMC   3777738 . PMID   23177956.
  160. Soltan M, Girguis J (8 May 2017). "How to approach the mental state examination". BMJ. 357: j1821. doi:10.1136/sbmj.j1821. PMID   31055448. S2CID   145820368 . Retrieved 9 January 2020.
  161. Lindenmayer JP (1 December 2017). "Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review". Innovations in Clinical Neuroscience. 14 (11–12): 73–76. PMC   5788254 . PMID   29410940.
  162. "Diagnosis of schizophrenia". Australian Department of Health. 10 January 2019. Retrieved 28 January 2020.
  163. "Schizophrenia – Diagnosis". UK National Health Service. 23 October 2017. Retrieved 28 January 2020.
  164. Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, Werge T (2005). "Reliability of clinical ICD-10 schizophrenia diagnoses". Nordic Journal of Psychiatry. 59 (3): 209–212. doi:10.1080/08039480510027698. PMID   16195122. S2CID   24590483.
  165. 1 2 3 Richard-Devantoy S, Olie JP, Gourevitch R (December 2009). "[Risk of homicide and major mental disorders: a critical review]". L'Encephale. 35 (6): 521–530. doi:10.1016/j.encep.2008.10.009. PMID   20004282.
  166. 1 2 Staedt J, Hauser M, Gudlowski Y, Stoppe G (February 2010). "Sleep disorders in schizophrenia". Fortschritte der Neurologie-Psychiatrie. 78 (2): 70–80. doi:10.1055/s-0028-1109967. PMID   20066610. S2CID   260137215.
  167. 1 2 Pocivavsek A, Rowland LM (13 January 2018). "Basic Neuroscience Illuminates Causal Relationship Between Sleep and Memory: Translating to Schizophrenia". Schizophrenia Bulletin. 44 (1): 7–14. doi: 10.1093/schbul/sbx151 . PMC   5768044 . PMID   29136236.
  168. 1 2 Monti JM, BaHammam AS, Pandi-Perumal SR, Bromundt V, Spence DW, Cardinali DP, et al. (June 2013). "Sleep and circadian rhythm dysregulation in schizophrenia". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 209–216. doi:10.1016/j.pnpbp.2012.12.021. hdl: 11336/3858 . PMID   23318689. S2CID   19626589.
  169. Faulkner SM, Bee PE, Meyer N, Dijk DJ, Drake RJ (August 2019). "Light therapies to improve sleep in intrinsic circadian rhythm sleep disorders and neuro-psychiatric illness: A systematic review and meta-analysis". Sleep Medicine Reviews. 46: 108–123. doi: 10.1016/j.smrv.2019.04.012 . PMID   31108433.
  170. Assimakopoulos K, Karaivazoglou K, Skokou M, Kalogeropoulou M, Kolios P, Gourzis P, et al. (March 2018). "Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia: A Systematic Review". Medicines. 5 (2): 27. doi: 10.3390/medicines5020027 . PMC   6023503 . PMID   29587340.
  171. Dieset I, Andreassen O, Haukvik U (2016). "Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span". Schizophrenia Bulletin. 42 (6): 1316–1319. doi: 10.1093/schbul/sbw028 . PMC   5049521 . PMID   27033328.
  172. Schrimpf LA, Aggarwal A, Lauriello J (June 2018). "Psychosis". Continuum (Minneap Minn). 24 (3): 845–860. doi:10.1212/CON.0000000000000602. PMID   29851881. S2CID   243933980.
  173. Bottas A (15 April 2009). "Comorbidity: Schizophrenia With Obsessive-Compulsive Disorder". Psychiatric Times. 26 (4). Archived from the original on 3 April 2013.
  174. OConghaile A, DeLisi LE (May 2015). "Distinguishing schizophrenia from posttraumatic stress disorder with psychosis". Curr Opin Psychiatry. 28 (3): 249–255. doi:10.1097/YCO.0000000000000158. PMID   25785709. S2CID   12523516.
  175. Murray ED, Buttner N, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.). Bradley's neurology in clinical practice. Vol. 1 (6th ed.). Philadelphia, PA: Elsevier/Saunders. pp. 92–111. ISBN   978-1-4377-0434-1.
  176. Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, et al. (November 2021). "Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis". JAMA Psychiatry. 78 (11): 1238–1248. doi:10.1001/jamapsychiatry.2021.2130. PMC   8374744 . PMID   34406325.
  177. Cannon TD, Cornblatt B, McGorry P (May 2007). "The empirical status of the ultra high-risk (prodromal) research paradigm". Schizophrenia Bulletin. 33 (3): 661–664. doi:10.1093/schbul/sbm031. PMC   2526144 . PMID   17470445.
  178. Puntis S, Minichino A, De Crescenzo F, Cipriani A, Lennox B, Harrison R (November 2020). "Specialised early intervention teams for recent-onset psychosis". Cochrane Database Syst Rev. 11 (11): CD013288. doi:10.1002/14651858.CD013288.pub2. PMC   8092671 . PMID   33135811. p. 22: There is low-certainty evidence for the use of SEl services in comparison to TAU for a small reduction in psychiatric hospitalisation, and moderate-certainty evidence of a large effect of reduction in disengagement from mental health services. There is moderate-certainty evidence that SEI results in a small reduction of positive (hallucinations, delusions and disordered thinking) and negative symptoms (social withdrawal, flat or blunted affect, and poverty of speech) and low-certainty evidence that it greatly increases satisfaction in care, while there is low-certainty evidence that it improves general functioning and the likelihood of recovery. These effects were only observed during treatment and there was no evidence that outcomes are improved after the treatment has finished, although these were based on only one trial.
  179. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T (January 2013). "Early interventions to prevent psychosis: systematic review and meta-analysis". BMJ. 346: f185. doi:10.1136/bmj.f185. PMC   3548617 . PMID   23335473.
  180. 1 2 Taylor M, Jauhar S (September 2019). "Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia". Therapeutic Advances in Psychopharmacology. 9: 204512531987003. doi:10.1177/2045125319870033. PMC   6732843 . PMID   31523418.
  181. Weiden PJ (July 2016). "Beyond Psychopharmacology: Emerging Psychosocial Interventions for Core Symptoms of Schizophrenia". Focus (American Psychiatric Publishing). 14 (3): 315–327. doi:10.1176/appi.focus.20160014. PMC   6526802 . PMID   31975812.
  182. McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (March 2007). "Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial". The American Journal of Psychiatry. 164 (3): 437–441. doi:10.1176/appi.ajp.164.3.437. PMID   17329468.
  183. Souaiby L, Gaillard R, Krebs MO (August 2016). "[Duration of untreated psychosis: A st